Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 48
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Burden of postmenopausal breast cancer attributable to excess body weight, comparative study of body mass index and CUN-BAE in MCC-Spain study

  • Cubelos-Fernández, Naiara
  • Davila-Batista, Veronica|||0000-0001-8888-395X
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Amiano, Pilar
  • Ardanaz, Eva
  • Delgado Sillero, Irene
  • Llorca, Javier|||0000-0001-8569-861X
  • Tardón, Guillermo Fernández
  • Alguacil, Juan|||0000-0003-2703-9725
  • Vanaclocha Espí, Mercedes|||0000-0002-7202-2861
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Aragonés, Nuria
  • Dorronsoro, Ane
  • Guevara, Marcela|||0000-0001-9242-6364
  • Reguero Celada, Sofía
  • Pollán, Marina|||0000-0002-4328-1565
  • Martín, Vicente|||0000-0003-0552-2804
10% of postmenopausal breast cancer cases are attributed to a high body mass index (BMI). BMI underestimates body fat, particularly in older women, and therefore the cancer burden attributable to obesity may be even higher. However, this is not clear. CUN-BAE (Clínica Universidad de Navarra-Body Adiposity Estimator) is an accurate validated estimator of body fat, taking into account sex and age. The objective of this study was to compare the burden of postmenopausal breast cancer attributable to excess body fat calculated using BMI and CUN-BAE. This case-control study included 1033 cases of breast cancer and 1143 postmenopausal population controls from the multicase-control MCC-Spain study. Logistic regression models were used to calculate odds ratios (ORs). The population attributable fraction (PAF) of excess weight related to breast cancer was estimated with both anthropometric measures. Stratified analyses were carried out for hormone receptor type. Excess body weight attributable to the risk of breast cancer was 23.0% when assessed using a BMI value ≥30 kg/m 2 and 38.0% when assessed using a CUN-BAE value of ≥40% body fat. Hormone receptor stratification showed that these differences in PAFs were only observed in hormone receptor positive cases, with an estimated burden of 19.9% for BMI and 41.9% for CUN-BAE. These findings suggest that the significance of excess body fat in postmenopausal hormone receptor positive breast cancer could be underestimated when assessed using only BMI. Accurate estimation of the cancer burden attributable to obesity is crucial for planning effective prevention initiatives.
Repisalud
Publication Artículo científico (JournalArticle)

Reproductive risk factors in breast cancer and genetic hormonal pathways: a gene-environment interaction in the MCC-Spain project

  • Dierssen-Sotos, Trinidad
  • Palazuelos-Calderón, Camilo
  • Jimenez-Moleon, Jose J.
  • Aragones, Nuria
  • Altzibar, Jone M
  • Castaño-Vinyals, Gemma
  • Martín-Sánchez, Vicente
  • Gómez-Acebo, Inés
  • Guevara, Marcela
  • Tardón, Adonina
  • Perez-Gomez, Beatriz
  • Amiano, Pilar
  • Moreno, Victor
  • Molina, Antonio J
  • Alonso-Molero, Jéssica
  • Moreno-Iribas, Conchi
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
BACKGROUND: Reproductive factors are well known risk factors for breast cancer; however, little is known about how genetic variants in hormonal pathways interact with that relationship. METHODS: One thousand one hundred thirty nine cases of breast cancer in women and 1322 frequency-matched controls were compared. Genetic variants in hormonal pathways (identified in the Kyoto Encyclopedia of Genes and Genomes) were screened according to their relationship with breast cancer using the Cochran-Armitage statistic. Information on reproductive factors was obtained using a face-to-face questionnaire. The interaction among the selected genetic variants and reproductive factors was tested with logistic regression. RESULTS: Concerning C allele in rs2229712, compared to nulliparity in non-carriers the ORs for 1-2 and > 2 deliveries were 0.48 (0.28-0.81) and 0.34 (0.19-0.59), and in C carriers they were 0.92 (0.42-1.98) and 0.71 (0.31-1.61). Similar results were found in women carrying the C allele in rs1269851. Carriers of Allele T in rs35652107 and allele C in rs6018027 had the delivery number effect more pronounced. CONCLUSIONS: The number of deliveries had a dose-response protective effect on breast cancer; women carrying C allele in rs2229712 did not benefit from this protective effect.
Repisalud
Publication Artículo científico (JournalArticle)

Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study

  • Ibáñez-Sanz, Gemma
  • Díez-Villanueva, Anna
  • Vilorio-Marqués, Laura
  • Gracia, Esther
  • Aragones, Nuria
  • Olmedo-Requena, Rocío
  • Llorca, Javier
  • Vidán, Juana
  • Amiano, Pilar
  • Nos, Pilar
  • Fernández-Tardón, Guillermo
  • Rada, Ricardo
  • Chirlaque, María-Dolores
  • Guinó, Elisabet
  • Dávila-Batista, Verónica
  • Castaño-Vinyals, Gemma
  • Perez-Gomez, Beatriz
  • Mirón-Pozo, Benito
  • Dierssen-Sotos, Trinidad
  • Etxeberria, Jaione
  • Molinuevo, Amaia
  • Álvarez-Cuenllas, Begoña
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Moreno, Victor
A safe and effective colorectal cancer (CRC) chemoprevention agent remains to be discovered. We aim to evaluate the association between the use of glucosamine and/or chondroitin sulphate and risk of colorectal cancer (CRC) in the MCC-Spain study, a case-control study performed in Spain that included 2140 cases of CRC and 3950 population controls. Subjects were interviewed on sociodemographic factors, lifestyle, family and medical history and regular drug use. Adjusted odds ratios and their 95% confidence intervals were estimated. The reported frequency of chondroitin and/or glucosamine use was 2.03% in controls and 0.89% in cases. Users had a reduced risk of CRC (OR: 0.47; 95% CI: 0.28-0.79), but it was no longer significant when adjusted for NSAID (nonsteroidal anti-inflammatory drugs) use (OR: 0.82; 95% CI: 0.47-1.40). A meta-analysis with previous studies suggested a protective effect, overall and stratified by NSAID use (OR: 0.77; 95% CI: 0.62-0.97). We have not found strong evidence of an independent preventive effect of CG on CRC in our population because the observed effects of our study could be attributed to NSAIDs concurrent use. These results merit further research due to the safety profile of these drugs.
Repisalud
Publication Artículo científico (JournalArticle)

Colorectal cancer, sun exposure and dietary vitamin D and calcium intake in the MCC-Spain study

  • Vallès, Xavier
  • Alonso, María Henar
  • López-Caleya, Juan Francisco
  • Díez-Obrero, Virginia
  • Dierssen-Sotos, Trinidad
  • Lope Carvajal, Virginia
  • Molina-Barceló, Ana
  • Chirlaque, María Dolores
  • Jimenez-Moleon, Jose J.
  • Fernández Tardón, Guillermo
  • Castilla Catalán, Jesús
  • Amiano, Pilar
  • Capelo, Rocío
  • Castaño-Vinyals, Gemma
  • Guinó, Elisabet
  • Molina de la Torre, Antonio José
  • Moreno-Iribas, Conchi
  • Perez-Gomez, Beatriz
  • Aragones, Nuria
  • Llorca, Javier
  • Martín, Vicente
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Moreno, Victor
OBJECTIVES: To explore the association of colorectal cancer with environmental solar radiation and sun exposure behavior, considering phenotypic variables (eye color, hair color and skin phenotype), dietary intake of vitamin D and calcium, and socio-demographic factors. STUDY DESIGN: Multicenter population-based frequency matched case-control study in Spain (MCC-Spain), with 2140 CRC cases and 3950 controls. METHODS: Data were obtained through personal interviews using a structured epidemiological questionnaire that included socio-demographic data, residential history, environmental exposures, behavior, phenotypic and dietary information. An environmental-lifetime sun exposure score was constructed combining residential history and average daily solar radiation, direct and diffuse. Logistic regression was used to explore the association between different variables. A structural equation model was used to verify the associations of the conceptual model. RESULTS: We found a lower risk of CRC in subjects frequently exposed to sunlight during the previous summer and skin burning due to sun exposure. No association was observed in relation to the residential solar radiation scores. Subjects with light eye or light hair colors had a lower risk of CRC that those with darker colors. Dietary calcium and vitamin D were also protective factors, but not in the multivariate model. The structural equation model analysis suggested that higher sun exposure was associated with a decreased risk of CRC, as well as dietary intake of calcium and vitamin D, and these factors are correlated among themselves and with environmental solar radiation and skin phenotypes. CONCLUSION: The results agree with previous observations that sun exposure, dietary vitamin D and calcium intake, and serum 25(OH)D concentration reduce the risk of CRC and indicate that these factors may be relevant for cancer prevention.
Repisalud
Publication Artículo científico (JournalArticle)

Helicobacter pylori Antibody Reactivities and Colorectal Cancer Risk in a Case-control Study in Spain

  • Fernandez de Larrea-Baz, Nerea
  • Michel, Angelika
  • Romero, Beatriz
  • Perez-Gomez, Beatriz
  • Moreno, Victor
  • Martín, Vicente
  • Dierssen-Sotos, Trinidad
  • Jimenez-Moleon, Jose J.
  • Castilla Catalán, Jesús
  • Tardón, Adonina
  • Ruiz, Irune
  • Peiró, Rosana
  • Tejada, Antonio
  • Chirlaque, María-Dolores
  • Butt, Julia A
  • Olmedo-Requena, Rocío
  • Gómez-Acebo, Inés
  • Linares, Pedro
  • Boldo, Elena
  • Castells, Antoni
  • Pawlita, Michael
  • Castaño-Vinyals, Gemma
  • Kogevinas, Manolis
  • de Sanjose, Silvia
  • Pollan-Santamaria, Marina
  • Del Campo, Rosa
  • Waterboer, Tim
  • Aragones, Nuria
Background: Several studies have suggested that Helicobacter pylori (H. pylori) infection is a risk factor for colorectal cancer (CRC), while others have not confirmed this hypothesis. This work aimed to assess the relation of CRC with H. pylori seropositivity and with seropositivity to 16 H. pylori proteins, in the MultiCase-Control study, MCC-Spain. Methods: MCC-Spain is a multicase-control study carried out in Spain from 2008 to 2013. In total, 2,140 histologically-confirmed incident CRC cases and 4,098 population-based controls were recruited. Controls were frequency-matched by sex, age, and province. Epidemiological data were collected through a questionnaire fulfilled by face-to-face interviews and a self-administered food-frequency questionnaire. Seroreactivities against 16 H. pylori proteins were determined in 1,488 cases and 2,495 controls using H. pylori multiplex serology. H. pylori seropositivity was defined as positivity to ≥4 proteins. Multivariable logistic regression mixed models were used to estimate odds ratios (OR) and 95% confidence intervals (CI). Results:H. pylori seropositivity was not associated with increased CRC risk (OR = 0.91; 95% CI: 0.71-1.16). Among H. pylori seropositive subjects, seropositivity to Cagδ showed a lower CRC risk, and risk decreased with increasing number of proteins seropositive. Seropositivity to the most recognized virulence factors, CagA and VacA, was not associated with a higher CRC risk. No statistically significant heterogeneity was identified among tumor sites, although inverse relations were stronger for left colon cancer. An interaction with age and sex was found: H. pylori seropositivity was associated with a lower CRC risk in men younger than 65 and with a higher risk in older women. Conclusions: Our results suggest that neither H. pylori seropositivity, nor seropositivity to the virulence factor CagA are associated with a higher CRC risk. A possible effect modification by age and sex was identified.
Repisalud
Publication Artículo científico (JournalArticle)

Validating a breast cancer score in Spanish women. The MCC-Spain study

  • Dierssen-Sotos, Trinidad
  • Gómez-Acebo, Inés
  • Palazuelos, Camilo
  • Fernandez-Navarro, Pablo L
  • Altzibar, Jone M
  • González-Donquiles, Carmen
  • Ardanaz, Eva
  • Bustamante, Mariona
  • Alonso-Molero, Jéssica
  • Vidal, Carmen
  • Bayo-Calero, Juan
  • Tardón, Adonina
  • Salas, Dolores
  • Marcos-Gragera, Rafael
  • Moreno, Victor
  • Rodríguez-Cundín, Paz
  • Vinyals, Gemma Castaño
  • Ederra, María
  • Vilorio-Marqués, Laura
  • Amiano, Pilar
  • Perez-Gomez, Beatriz
  • Aragones, Nuria
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
A breast-risk score, published in 2016, was developed in white-American women using 92 genetic variants (GRS92), modifiable and non-modifiable risk factors. With the aim of validating the score in the Spanish population, 1,732 breast cancer cases and 1,910 controls were studied. The GRS92, modifiable and non-modifiable risk factor scores were estimated via logistic regression. SNPs without available genotyping were simulated as in the aforementioned 2016 study. The full model score was obtained by combining GRS92, modifiable and non-modifiable risk factor scores. Score performances were tested via the area under the ROC curve (AUROC), net reclassification index (NRI) and integrated discrimination improvement (IDI). Compared with non-modifiable and modifiable factor scores, GRS92 had higher discrimination power (AUROC: 0.6195, 0.5885 and 0.5214, respectively). Adding the non-modifiable factor score to GRS92 improved patient classification by 23.6% (NRI = 0.236), while the modifiable factor score only improved it by 7.2%. The full model AUROC reached 0.6244. A simulation study showed the ability of the full model for identifying women at high risk for breast cancer. In conclusion, a model combining genetic and risk factors can be used for stratifying women by their breast cancer risk, which can be applied to individualizing genetic counseling and screening recommendations.
Repisalud
Publication Artículo científico (JournalArticle)

Association between Polyphenol Intake and Gastric Cancer Risk by Anatomic and Histologic Subtypes: MCC-Spain

  • Rubín-García, María
  • Vitelli-Storelli, Facundo
  • Molina, Antonio José
  • Zamora-Ros, Raúl
  • Aragones, Nuria
  • Adarnaz, Eva
  • Castaño-Vinyals, Gemma
  • Obón-Santacana, Mireia
  • Gómez-Acebo, Inés
  • Molina-Barceló, Ana
  • Fernández-Tardón, Guillermo
  • Jimenez-Moleon, Jose J.
  • Alguacil, Juan
  • Chirlaque, María-Dolores
  • Toledo, Estefanía
  • Perez-Gomez, Beatriz
  • Pollan-Santamaria, Marina
  • Kogevinas, Manolis
  • Martín, Vicente
Several anticancer properties have been largely attributed to phenolics in in vivo and in vitro studies, but epidemiologic evidence is still scarce. Furthermore, some classes have not been studied in relation to gastric cancer (GC). The aim of this study was to assess the relationship between the intake of phenolic acids, stilbenes, and other phenolics and the risk of developing GC and its anatomical and histological subtypes. We used data from a multi-case-control study (MCC-Spain) obtained from different regions of Spain. We included 2700 controls and 329 GC cases. Odds ratios (ORs) were calculated using mixed effects logistic regression considering quartiles of phenolic intake. Our results showed an inverse association between stilbene and lignan intake and GC risk (ORQ4 vs. Q1 = 0.47; 95% CI: 0.32-0.69 and ORQ4 vs. Q1 = 0.53; 95% CI: 0.36-0.77, respectively). We found no overall association between total phenolic acid and other polyphenol class intake and GC risk. However, hydroxybenzaldehydes (ORQ4 vs. Q1 = 0.41; 95% CI: 0.28-0.61), hydroxycoumarins (ORQ4 vs. Q1 = 0.49; 95% CI: 0.34-0.71), and tyrosols (ORQ4 vs. Q1 = 0.56; 95% CI: 0.39-0.80) were inversely associated with GC risk. No differences were found in the analysis by anatomical or histological subtypes. In conclusion, a diet high in stilbenes, lignans, hydroxybenzaldehydes, hydroxycoumarins, and tyrosols was associated with a lower GC risk. Further prospective studies are needed to confirm our results.
Repisalud
Publication Artículo científico (JournalArticle)

Risk of breast cancer and residential proximity to industrial installations: New findings from a multicase-control study (MCC-Spain)

  • García-Pérez, Javier
  • Lope Carvajal, Virginia
  • Perez-Gomez, Beatriz
  • Molina, Antonio José
  • Tardón, Adonina
  • Díaz Santos, María Angustias
  • Ardanaz, Eva
  • O'Callaghan-Gordo, Cristina
  • Altzibar, Jone M
  • Gómez-Acebo, Inés
  • Moreno, Victor
  • Peiró, Rosana
  • Marcos-Gragera, Rafael
  • Kogevinas, Manolis
  • Aragones, Nuria
  • Lopez-Abente, Gonzalo
  • Pollan-Santamaria, Marina
Breast cancer is the most frequent tumor in women worldwide, although well-established risk factors account for 53%-55% of cases. Therefore, other risk factors, including environmental exposures, may explain the remaining variation. Our objective was to assess the relationship between risk of breast cancer and residential proximity to industries, according to categories of industrial groups and specific pollutants released, in the context of a population-based multicase-control study of incident cancer carried out in Spain (MCC-Spain). Using the current residence of cases and controls, this study was restricted to small administrative divisions, including both breast cancer cases (452) and controls (1511) in the 10 geographical areas recruiting breast cancer cases. Distances were calculated from the respective woman's residences to the 116 industries located in the study area. We used logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (95%CIs) for categories of distance (between 1 km and 3 km) to industrial plants, adjusting for matching variables and other confounders. Excess risk (OR; 95%CI) of breast cancer was found near industries overall (1.30; 1.00-1.69 at 3 km), particularly organic chemical industry (2.12; 1.20-3.76 at 2.5 km), food/beverage sector (1.87; 1.26-2.78 at 3 km), ceramic (4.71; 1.62-13.66 at 1.5 km), surface treatment with organic solvents (2.00; 1.23-3.24 at 3 km), and surface treatment of plastic and metals (1.51; 1.06-2.14 at 3 km). By pollutants, the excess risk (OR; 95%CI) was detected near industries releasing pesticides (2.09; 1.14-3.82 at 2 km), and dichloromethane (2.09; 1.28-3.40 at 3 km). Our results suggest a possible increased risk of breast cancer in women living near specific industrial plants and support the need for more detailed exposure assessment of certain agents released by these plants.
Repisalud
Publication Artículo científico (JournalArticle)

Pigmentation phototype and prostate and breast cancer in a select Spanish population-A Mendelian randomization analysis in the MCC-Spain study

  • Gómez-Acebo, Inés
  • Dierssen-Sotos, Trinidad
  • Palazuelos, Camilo
  • Fernandez-Navarro, Pablo L
  • Castaño-Vinyals, Gemma
  • Alonso-Molero, Jéssica
  • Urtiaga, Carmen
  • Fernández-Villa, Tania
  • Ardanaz, Eva
  • Rivas-Del-Fresno, Manuel
  • Molina-Barceló, Ana
  • Jimenez-Moleon, Jose J.
  • García-Martínez, Lidia
  • Amiano, Pilar
  • Rodríguez-Cundín, Paz
  • Moreno, Victor
  • Perez-Gomez, Beatriz
  • Aragones, Nuria
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
INTRODUCTION: Phototype has been associated with an increased risk of prostate cancer, and it is yet unknown if it is related to other hormone-dependent cancers, such as breast cancer or whether this association could be considered causal. METHODS: We examined the association between the phototype and breast and prostate cancers using a Mendelian randomization analysis. We studied 1,738 incident cases of breast cancer and another 817 cases of prostate cancer. To perform a Mendelian randomization analysis on the phototype-cancer relationship, a genetic pigmentation score was required that met the following criteria: (1) the genetic pigmentation score was associated with phototype in controls; (2) the genetic pigmentation score was not associated with confounders in the relationship between phototype and cancer, and (3) the genetic pigmentation score was associated with cancer only through its association with phototype. Once this genetic score is available, the association between genetic pigmentation score and cancer can be identified as the association between phototype and cancer. RESULTS: The association between the genetic pigmentation score and phototype in controls showed that a higher genetic pigmentation score was associated with fair skin, blond hair, blue eyes and the presence of freckles. Applying the Mendelian randomization analysis, we verified that there was no association between the genetic pigmentation score and cancers of the breast and prostate. CONCLUSIONS: Phototype is not associated with breast or prostate cancer.
Repisalud
Publication Artículo científico (JournalArticle)

Validation of self-reported perception of proximity to industrial facilities: MCC-Spain study

  • Castelló Pastor, Adela
  • Perez-Gomez, Beatriz
  • Lora-Pablos, David
  • Lope Carvajal, Virginia
  • Castaño-Vinyals, Gemma
  • Vitelli-Storelli, Facundo
  • Dierssen-Sotos, Trinidad
  • Amiano, Pilar
  • Guevara, Marcela
  • Moreno, Victor
  • Lozano-Lorca, Macarena
  • Tardón, Adonina
  • Alguacil, Juan
  • Hernández-García, Marta
  • Marcos-Gragera, Rafael
  • Chirlaque López, María Dolores
  • Ardanaz, Eva
  • Ibarluzea, Jesús
  • Gómez-Acebo, Inés
  • Molina, Antonio J
  • O'Callaghan-Gordo, Cristina
  • Aragones, Nuria
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • García-Pérez, Javier
BACKGROUND: Self-reported data about environmental exposures can lead to measurement error. OBJECTIVES: To validate the self-reported perception of proximity to industrial facilities. METHODS: MCC-Spain is a population-based multicase-control study of cancer in Spain that recruited incident cases of breast, colorectal, prostate, and stomach cancer. The participant's current residence and the location of the industries were geocoded, and the linear distance between them was calculated (gold standard). The epidemiological questionnaire included a question to determine whether the participants perceived the presence of any industry at ≤1 km from their residences. Sensitivity and specificity of individuals' perception of proximity to industries were estimated as measures of classification accuracy, and the area under the curve (AUC) and adjusted odds ratios (aORs) of misclassification were calculated as measures of discrimination. Analyses were performed for all cases and controls, and by tumor location, educational level, sex, industrial sector, and length of residence. Finally, aORs of cancer associated with real and self-reported distances were calculated to explore differences in the estimation of risk between these measures. RESULTS: Sensitivity of the questionnaire was limited (0.48) whereas specificity was excellent (0.89). AUC was sufficient (0.68). Participants with breast (aOR(95%CI) = 2.03 (1.67;2.46)), colorectal (aOR(95%CI) = 1.41 (1.20;1.64)) and stomach (aOR(95%CI) = 1.59 (1.20;2.10)) cancer showed higher risk of misclassification than controls. This risk was higher for lower educational levels (aOR<primaryvs.university (95%CI) = 1.78 (1.44;2.20)), among younger participants (aOR22-54 yearsvs. 73-85 years (95%CI) = 1.32 (1.09;1.60)), and for some industrial sectors: pharmaceutical (aOR(95%CI) = 29.02 (19.52;43.14)), galvanization (aOR(95%CI) = 14.14 (6.78;29.47)), and ceramic (aOR(95%CI) = 12.73 (7.22;22.44)). Participants living ≤1 year in the study area showed a lower risk of misclassification ((aOR≤1vs.>15 years (95%CI) = 0.56 (0.36;0.85)). The use of self-reported proximity vs. real distance to industrial facilities biased the effect on cancer risk towards the nullity. CONCLUSIONS: Self-reported distance to industrial facilities can be a useful tool for hypothesis generation, but hypothesis-testing studies should use real distance to report valid conclusions. The sensitivity of the question might be improved with a more specific formulation.
Repisalud
Publication Artículo científico (JournalArticle)

Risk Model for Prostate Cancer Using Environmental and Genetic Factors in the Spanish Multi-Case-Control (MCC) Study

  • Gómez-Acebo, Inés
  • Dierssen-Sotos, Trinidad
  • Fernandez-Navarro, Pablo L
  • Palazuelos, Camilo
  • Moreno, Victor
  • Aragones, Nuria
  • Castaño-Vinyals, Gemma
  • Jimenez-Moleon, Jose J.
  • Ruiz-Cerdá, Jose Luis
  • Perez-Gomez, Beatriz
  • Ruiz-Dominguez, José Manuel
  • Molero, Jessica Alonso
  • Pollan-Santamaria, Marina
  • Kogevinas, Manolis
  • Llorca, Javier
Prostate cancer (PCa) is the second most common cancer among men worldwide. Its etiology remains largely unknown compared to other common cancers. We have developed a risk stratification model combining environmental factors with family history and genetic susceptibility. 818 PCa cases and 1,006 healthy controls were compared. Subjects were interviewed on major lifestyle factors and family history. Fifty-six PCa susceptibility SNPs were genotyped. Risk models based on logistic regression were developed to combine environmental factors, family history and a genetic risk score. In the whole model, compared with subjects with low risk (reference category, decile 1), those carrying an intermediate risk (decile 5) had a 265% increase in PCa risk (OR = 3.65, 95% CI 2.26 to 5.91). The genetic risk score had an area under the ROC curve (AUROC) of 0.66 (95% CI 0.63 to 0.68). When adding the environmental score and family history to the genetic risk score, the AUROC increased by 0.05, reaching 0.71 (95% CI 0.69 to 0.74). Genetic susceptibility has a stronger risk value of the prediction that modifiable risk factors. While the added value of each SNP is small, the combination of 56 SNPs adds to the predictive ability of the risk model.
Repisalud
Publication Artículo científico (JournalArticle)

Social mobility and healthy behaviours from a gender perspective in the Spanish multicase-control study (MCC-Spain)

  • Pinto-Carbó, M
  • Peiró-Pérez, R
  • Molina-Barceló, Ana
  • Vanaclocha-Espi, Mercedes
  • Alguacil, Juan
  • Castaño-Vinyals, Gemma
  • O'Callaghan-Gordo, Cristina
  • Gràcia-Lavedan, Esther
  • Perez-Gomez, Beatriz
  • Lope Carvajal, Virginia
  • Aragones, Nuria
  • Molina, A J
  • Fernández-Villa, Tania
  • Gil-Majuelo, L
  • Amiano, P
  • Dierssen-Sotos, Trinidad
  • Gómez-Acebo, Inés
  • Guevara, M
  • Moreno-Iribas, C
  • Obón-Santacana, Mireia
  • Rodríguez-Suárez, M M
  • Salcedo-Bellido, I
  • Delgado-Parrilla, A
  • Marcos-Gragera, R
  • Chirlaque, María-Dolores
  • Kogevinas, M
  • Pollan-Santamaria, Marina
  • Salas, D
There is evidence for the influence of socioeconomic status (SES) on healthy behaviours but the effect of social mobility (SM) is not yet well known. This study aims to analyse the influence of origin and destination SES (O-SES and D-SES) and SM on healthy behaviours and co-occurrence, from an integrated gender and age perspective. Data were obtained from the controls of MCC-Spain between 2008-2013 (3,606 participants). Healthy behaviours considered: healthy diet, moderate alcohol consumption, non-smoking and physical activity. SM was categorized as stable high, upward, stable medium, downward or stable low. Binary and multinomial logistic regression models were adjusted. Those aged <65, with a low O-SES, D-SES and stable low SM are less likely to have healthy behaviours in the case of both women (physically active: OR = 0.65 CI = 0.45-0.94, OR = 0.71 CI = 0.52-0.98, OR = 0.61 CI = 0.41-0.91) and men (non-smokers: OR = 0.44 CI = 0.26-0.76, OR = 0.54 CI = 0.35-0.83, OR = 0.41 CI 0.24-0.72; physically active: OR = 0.57 CI = 0.35-0.92, OR = 0.64 CI = 0.44-0.95, OR = 0.53 CI = 0.23-0.87). However, for those aged ≥65, this probability is higher in women with a low O-SES and D-SES (non-smoker: OR = 8.09 CI = 4.18-15.67, OR = 4.14 CI = 2.28-7.52; moderate alcohol consumption: OR = 3.00 CI = 1.45-6.24, OR = 2.83 CI = 1.49-5.37) and in men with a stable low SM (physically active: OR = 1.52 CI = 1.02-1.26). In the case of men, the same behaviour pattern is observed in those with a low O-SES as those with upward mobility, with a higher probability of co-occurring behaviours (three-to-four behaviours: OR = 2.00 CI = 1.22-3.29; OR = 3.13 CI = 1.31-7.48). The relationship of O-SES, D-SES and SM with healthy behaviours is complex and differs according to age and gender.
Repisalud
Publication Artículo científico (JournalArticle)

Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results

  • Alonso-Molero, Jéssica
  • Molina, Antonio J
  • Jimenez-Moleon, Jose J.
  • Perez-Gomez, Beatriz
  • Martín, Vicente
  • Moreno, Victor
  • Amiano, Pilar
  • Ardanaz, Eva
  • de Sanjose, Silvia
  • Salcedo, Inmaculada
  • Fernández-Tardón, Guillermo
  • Alguacil, Juan
  • Salas, Dolores
  • Marcos-Gragera, Rafael
  • Chirlaque, María-Dolores
  • Aragones, Nuria
  • Castaño-Vinyals, Gemma
  • Pollan-Santamaria, Marina
  • Kogevinas, Manolis
  • Llorca, Javier
PURPOSE: Since 2016, the multicase-control study in Spain (MCC-Spain) has focused towards the identification of factors associated with cancer prognosis. Inception cohorts of patients with colorectal, breast and prostate cancers were assembled using the incident cases originally recruited. PARTICIPANTS: 2140 new cases of colorectal cancer, 1732 of breast cancer and 1112 of prostate cancer were initially recruited in 12 Spanish provinces; all cancers were incident and pathologically confirmed. Follow-up was obtained for 2097 (98%), 1685 (97%) and 1055 (94.9%) patients, respectively. FINDINGS TO DATE: Information gathered at recruitment included sociodemographic factors, medical history, lifestyle and environmental exposures. Biological samples were obtained, and 80% of patients were genotyped using a commercial exome array. The follow-up was performed by (1) reviewing medical records; (2) interviewing the patients by phone on quality of life; and (3) verifying vital status and cause of death in the Spanish National Death Index. Ninety-seven per cent of recruited patients were successfully followed up in 2017 or 2018; patient-years of follow-up were 30 914. Most colorectal cancers (52%) were at clinical stage II or lower at recruitment; 819 patients died in the follow-up and the 5-year survival was better for women (74.4%) than men (70.0%). 71% of breast cancers were diagnosed at stages I or II; 206 women with breast cancer died in the follow-up and the 5-year survival was 90.7%. 49% of prostate cancers were diagnosed at stage II and 32% at stage III; 119 patients with prostate cancer died in the follow-up and the 5-year survival was 93.7%. FUTURE PLANS: MCC-Spain has built three prospective cohorts on highly frequent cancers across Spain, allowing to investigate socioeconomic, clinical, lifestyle, environmental and genetic variables as putative prognosis factors determining survival of patients of the three cancers and the inter-relationship of these factors.
Repisalud
Publication Artículo científico (JournalArticle)

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study

  • Dierssen-Sotos, Trinidad
  • Gómez-Acebo, Inés
  • de Pedro, María
  • Perez-Gomez, Beatriz
  • Servitja, Sonia
  • Moreno, Victor
  • Amiano, Pilar
  • Fernandez-Villa, Tania
  • Barricarte, Aurelio
  • Tardón, Adonina
  • Diaz-Santos, Marian
  • Peiró-Pérez, Rosana
  • Marcos-Gragera, Rafael
  • Lope Carvajal, Virginia
  • Gràcia-Lavedan, Esther
  • Alonso, María Henar
  • Michelena-Echeveste, Maria Jesus
  • Garcia-Palomo, Andrés
  • Guevara, Marcela
  • Castaño-Vinyals, Gemma
  • Aragones, Nuria
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
BACKGROUND: The relationship between non-steroidal antiinflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce attention has been paid to their effect on different tumor categories (i.e.: ductal/non-ductal, stage at diagnosis or presence of hormonal receptors). METHODS: In this case-control study, we report the NSAID - breast cancer relationship in 1736 breast cancer cases and 1895 healthy controls; results are reported stratifying by the women's characteristics (i.e.: menopausal status or body mass index category) and by tumor characteristics. RESULTS: In our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0.76; 95 % Confidence Interval [CI]: 0.64-0.89), and similar results were found for acetic acid derivatives, propionic acid derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i.e. OR < 1), except in advanced clinical stage and triple negative cancers. CONCLUSION: Most NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to be restricted to hormone + or HER2+ cancers.
Repisalud
Publication Artículo científico (JournalArticle)

Mendelian randomization analysis rules out disylipidaemia as colorectal cancer cause

  • Ibáñez-Sanz, Gemma
  • Díez-Villanueva, Anna
  • Riera-Ponsati, Marina
  • Fernández-Villa, Tania
  • Fernandez-Navarro, Pablo L
  • Bustamante, Mariona
  • Llorca, Javier
  • Amiano, Pilar
  • Ascunce, Nieves
  • Fernández-Tardón, Guillermo
  • Salcedo Bellido, Inmaculada
  • Salas, Dolores
  • Capelo Álvarez, Rocío
  • Crous-Bou, Marta
  • Ortega-Valín, Luis
  • Perez-Gomez, Beatriz
  • Castaño-Vinyals, Gemma
  • Palazuelos, Camilo
  • Altzibar, Jone M
  • Ardanaz, Eva
  • Tardón, Adonina
  • Jimenez-Moleon, Jose J.
  • Olmos Juste, Valle
  • Aragones, Nuria
  • Pollan-Santamaria, Marina
  • Kogevinas, Manolis
  • Moreno, Victor
Dyslipidemia and statin use have been associated with colorectal cancer (CRC), but prospective studies have shown mixed results. We aimed to determine whether dyslipidemia is causally linked to CRC risk using a Mendelian randomization approach and to explore the association of statins with CRC. A case-control study was performed including 1336 CRC cases and 2744 controls (MCC-Spain). Subjects were administered an epidemiological questionnaire and were genotyped with an array which included polymorphisms associated with blood lipids levels, selected to avoid pleiotropy. Four genetic lipid scores specific for triglycerides (TG), high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), or total cholesterol (TC) were created as the count of risk alleles. The genetic lipid scores were not associated with CRC. The ORs per 10 risk alleles, were for TG 0.91 (95%CI: 0.72-1.16, p = 0.44), for HDL 1.14 (95%CI: 0.95-1.37, p = 0.16), for LDL 0.97 (95%CI: 0.81-1.16, p = 0.73), and for TC 0.98 (95%CI: 0.84-1.17, p = 0.88). The LDL and TC genetic risk scores were associated with statin use, but not the HDL or TG. Statin use, overall, was a non-significant protective factor for CRC (OR 0.84; 95%CI: 0.70-1.01, p = 0.060), but lipophilic statins were associated with a CRC risk reduction (OR 0.78; 95%CI 0.66-0.96, p = 0.018). Using the Mendelian randomization approach, our study does not support the hypothesis that lipid levels are associated with the risk of CRC. This study does not rule out, however, a possible protective effect of statins in CRC by a mechanism unrelated to lipid levels.
Repisalud
Publication Artículo científico (JournalArticle)

Burden of postmenopausal breast cancer attributable to excess body weight: comparative study of body mass index and CUN-BAE in MCC-Spain study

  • Cubelos-Fernández, Naiara
  • Dávila-Batista, Verónica
  • Fernández-Villa, Tania
  • Castaño-Vinyals, Gemma
  • Perez-Gomez, Beatriz
  • Amiano, Pilar
  • Ardanaz, Eva
  • Delgado Sillero, Irene
  • Llorca, Javier
  • Tardón, Guillermo Fernández
  • Alguacil, Juan
  • Vanaclocha-Espi, Mercedes
  • Marcos-Gragera, Rafael
  • Moreno, Victor
  • Aragones, Nuria
  • Dorronsoro, Ane
  • Guevara, Marcela
  • Reguero Celada, Sofía
  • Pollan-Santamaria, Marina
  • Kogevinas, Manolis
  • Martín, Vicente
Background: 10% of postmenopausal breast cancer cases are attributed to a high body mass index (BMI). BMI underestimates body fat, particularly in older women, and therefore the cancer burden attributable to obesity may be even higher. However, this is not clear. CUN-BAE (Clínica Universidad de Navarra-Body Adiposity Estimator) is an accurate validated estimator of body fat, taking into account sex and age. The objective of this study was to compare the burden of postmenopausal breast cancer attributable to excess body fat calculated using BMI and CUN-BAE. Methods: This case-control study included 1033 cases of breast cancer and 1143 postmenopausal population controls from the multicase-control MCC-Spain study. Logistic regression models were used to calculate odds ratios (ORs). The population attributable fraction (PAF) of excess weight related to breast cancer was estimated with both anthropometric measures. Stratified analyses were carried out for hormone receptor type. Results: Excess body weight attributable to the risk of breast cancer was 23.0% when assessed using a BMI value ≥30 kg/m2 and 38.0% when assessed using a CUN-BAE value of ≥40% body fat. Hormone receptor stratification showed that these differences in PAFs were only observed in hormone receptor positive cases, with an estimated burden of 19.9% for BMI and 41.9% for CUN-BAE. Conclusion: These findings suggest that the significance of excess body fat in postmenopausal hormone receptor positive breast cancer could be underestimated when assessed using only BMI. Accurate estimation of the cancer burden attributable to obesity is crucial for planning effective prevention initiatives.
Repisalud
Publication Artículo científico (JournalArticle)

The Dietary Inflammatory Index and Chronic Lymphocytic Leukaemia in the MCC Spain Study

  • Flores, José Carlos
  • Gràcia-Lavedan, Esther
  • Benavente, Yolanda
  • Amiano, Pilar
  • Romaguera, Dora
  • Costas, Laura
  • Robles, Claudia
  • Gonzalez-Barca, Eva
  • de la Banda, Esmeralda
  • Alonso, Esther
  • Aymerich, Marta
  • Campo, Elias
  • Dierssen-Sotos, Trinidad
  • Marcos-Gragera, Rafael
  • Rodríguez-Suárez, Marta María
  • Solans, Marta
  • Gimeno, Eva
  • Garcia Martin, Paloma
  • Aragones, Nuria
  • Shivappa, Nitin
  • Hebert, James R
  • Pollan-Santamaria, Marina
  • Kogevinas, Manolis
  • de Sanjose, Silvia
  • Castaño-Vinyals, Gemma
  • Casabonne, Delphine
Chronic inflammation plays a role in the development of chronic lymphocytic leukaemia (CLL), and diet might modulate chronic inflammation. This study aims to evaluate the association between the dietary inflammatory index (DII®) and CLL. A total of 366 CLL cases and 1643 controls of the Spanish multicase-control (MCC) Spain study were included. The inflammatory potential of the diet was assessed using the energy-adjusted dietary inflammatory index (E-DII) based on 30 items from a validated semi-quantitative food frequency questionnaire. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using logistic regression models controlling for potential confounders. Overall, a modest, non-statistically significant, positive association was observed between CLL and E-DII scores (OR for a one-unit increase in E-DII: 1.05 (CI 95%: 0.99, 1.12), p-value = 0.09 and by tertiles: ORT2vsT1: 1.20 (CI 95%: 0.90, 1.59); OR T3vsT1: 1.21 (CI 95%: 0.90, 1.62), p trend = 0.21). These results were independent from disease severity (p-het: 0.70), time from diagnosis (p-het: 0.67) and CLL treatment received (p-het: 0.56). No interactions were detected. In conclusion, the consumption of a diet with high pro-inflammatory components was not significantly associated with CLL. Changes towards a more pro-inflammatory dietary pattern in younger generations not included here warrant future research.
Repisalud
Publication Artículo científico (JournalArticle)

Dietary Inflammatory Index, Dietary Non-Enzymatic Antioxidant Capacity, and Colorectal and Breast Cancer Risk (MCC-Spain Study)

  • Obón-Santacana, Mireia
  • Romaguera, Dora
  • Gràcia-Lavedan, Esther
  • Molinuevo, Amaia
  • Molina-Montes, Esther
  • Shivappa, Nitin
  • Hebert, James R
  • Tardón, Adonina
  • Castaño-Vinyals, Gemma
  • Moratalla, Ferran
  • Guinó, Elisabet
  • Marcos-Gragera, Rafael
  • Azpiri, Mikel
  • Gil, Leire
  • Olmedo-Requena, Rocío
  • Lozano-Lorca, Macarena
  • Alguacil, Juan
  • Fernández-Villa, Tania
  • Martín, Vicente
  • Molina, Antonio J
  • Ederra, María
  • Moreno-Iribas, Conchi
  • Perez-Gomez, Beatriz
  • Aragones, Nuria
  • Castelló Pastor, Adela
  • Huerta, José María
  • Dierssen-Sotos, Trinidad
  • Gómez-Acebo, Inés
  • Molina-Barceló, Ana
  • Pollan-Santamaria, Marina
  • Kogevinas, Manolis
  • Moreno, Victor
  • Amiano, Pilar
Inflammation and antioxidant capacity have been associated with colorectal and breast cancer. We computed the dietary inflammatory index (DII®), and the total dietary non-enzymatic antioxidant capacity (NEAC) and associated them with colorectal and breast cancer risk in the population-based multi case-control study in Spain (MCC-Spain). We included 1852 colorectal cancer and 1567 breast cancer cases, and 3447 and 1486 population controls, respectively. DII score and NEAC were derived using data from a semi-quantitative validated food frequency questionnaire. Unconditional logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (95%CI) for energy-adjusted DII (E-DII), and a score combining E-DII and NEAC. E-DII was associated with colorectal cancer risk (OR = 1.93, highest quartile versus lowest, 95%CI:1.60-2.32; p-trend: <0.001); this increase was observed for both colon and rectal cancer. Less pronounced increased risks were observed for breast cancer (OR = 1.22, highest quartile versus lowest, 95%CI:0.99-1.52, p-trend: >0.10). The combined score of high E-DII scores and low antioxidant values were associated with colorectal cancer risk (OR = 1.48, highest quartile versus lowest, 95%CI: 1.26-1.74; p-trend: <0.001), but not breast cancer. This study provides evidence that a pro-inflammatory diet is associated with increased colorectal cancer risk while findings for breast cancer were less consistent.
Repisalud
Publication Artículo científico (JournalArticle)

Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study

  • Gómez-Acebo, Inés
  • Dierssen-Sotos, Trinidad
  • Mirones, Mónica
  • Perez-Gomez, Beatriz
  • Guevara, Marcela
  • Amiano, Pilar
  • Sala, María
  • Molina, Antonio J
  • Alonso-Molero, Jéssica
  • Moreno, Victor
  • Suarez-Calleja, Claudia
  • Molina-Barceló, Ana
  • Alguacil, Juan
  • Marcos-Gragera, Rafael
  • Fernández-Ortiz, María
  • Sanz-Guadarrama, Oscar
  • Castaño-Vinyals, Gemma
  • Gil-Majuelo, Leire
  • Moreno-Iribas, Conchi
  • Aragones, Nuria
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
The St Gallen Conference endorsed in 2013 a series of recommendations on early breast cancer treatment. The main purpose of this article is to ascertain the clinical factors associated with St Gallen-2013 recommendations accomplishment. A cohort of 1152 breast cancer cases diagnosed with pathological stage < 3 in Spain between 2008 and 2013 was begun and then followed-up until 2017/2018. Data on patient and tumour characteristics were obtained from medical records, as well as their first line treatment. First line treatments were classified in three categories, according on whether they included the main St Gallen-2013 recommendations, more than those recommended or less than those recommended. Multinomial logistic regression models were carried out to identify factors associated with this classification and Weibull regression models were used to find out the relationship between this classification and survival. About half of the patients were treated according to St Gallen recommendations; 21% were treated over what was recommended and 33% received less treatment than recommended. Factors associated with treatment over the recommendations were stage II (relative risk ratio [RRR] = 4.2, 2.9-5.9), cancer positive to either progesterone (RRR = 8.1, 4.4-14.9) or oestrogen receptors (RRR = 5.7, 3.0-11.0). Instead, factors associated with lower probability of treatment over the recommendations were age (RRR = 0.7 each 10 years, 0.6-0.8), poor differentiation (RRR = 0.09, 0.04-0.19), HER2 positive (RRR = 0.46, 0.26-0.81) and triple negative cancer (RRR = 0.03, 0.01-0.11). Patients treated less than what was recommended in St Gallen had cancers in stage 0 (RRR = 21.6, 7.2-64.5), poorly differentiated (RRR = 1.9, 1.2-2.9), HER2 positive (RRR = 3.4, 2.4-4.9) and luminal B-like subtype (RRR = 3.6, 2.6-5.1). Women over 65 years old had a higher probability of being treated less than what was recommended if they had luminal B-like, HER2 or triple negative cancer. Treatment over St Gallen was associated with younger women and less severe cancers, while treatment under St Gallen was associated with older women, more severe cancers and cancers expressing HER2 receptors.
Repisalud
Publication Artículo científico (JournalArticle)

Adherence to the Western, Prudent, and Mediterranean dietary patterns and chronic lymphocytic leukemia in the MCC-Spain study

  • Solans, Marta
  • Castelló Pastor, Adela
  • Benavente, Yolanda
  • Marcos-Gragera, Rafael
  • Amiano, Pilar
  • Gràcia-Lavedan, Esther
  • Costas, Laura
  • Robles, Claudia
  • Gonzalez-Barca, Eva
  • de la Banda, Esmeralda
  • Alonso, Esther
  • Aymerich, Marta
  • Campo, Elias
  • Dierssen-Sotos, Trinidad
  • Fernández-Tardón, Guillermo
  • Olmedo-Requena, Rocío
  • Gimeno, Eva
  • Castaño-Vinyals, Gemma
  • Aragones, Nuria
  • Kogevinas, Manolis
  • de Sanjose, Silvia
  • Pollan-Santamaria, Marina
  • Casabonne, Delphine
Diet is a modifiable risk factor for several neoplasms but evidence for chronic lymphocytic leukemia (CLL) is sparse. Previous studies examining the association between single-food items and CLL risk have yielded mixed results, while few studies have been conducted on overall diet, reporting inconclusive findings. This study aimed to evaluate the association between adherence to three dietary patterns and CLL in the multicase-control study (MCC-Spain) study. Anthropometric, sociodemographic, medical and dietary information was collected for 369 CLL cases and 1605 controls. Three validated dietary patterns, Western, Prudent and Mediterranean, were reconstructed in the MCC-Spain data. The association between adherence to each dietary pattern and CLL was assessed, overall and by Rai stage, using mixed logistic regression models adjusted for potential confounders. High adherence to a Western dietary pattern (i.e. high intake of high-fat dairy products, processed meat, refined grains, sweets, caloric drinks, and convenience food) was associated with CLL [ORQ4 vs. Q1=1.63 (95%CI 1.11; 2.39); P-trend=0.02; OR 1-SD increase=1.19 (95%CI: 1.03; 1.37)], independently of Rai stages. No differences in the association were observed according to sex, Body Mass Index, energy intake, tobacco, physical activity, working on a farm, or family history of hematologic malignancies. No associations were observed for Mediterranean and Prudent dietary patterns and CLL. This study provides the first evidence for an association between a Western dietary pattern and CLL, suggesting that a proportion of CLL cases could be prevented by modifying dietary habits. Further research, especially with a prospective design, is warranted to confirm these findings.
Repisalud
Publication Artículo científico (JournalArticle)

Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study

  • Peremiquel-Trillas, Paula
  • Benavente, Yolanda
  • Martín-Bustamante, Mayte
  • Casabonne, Delphine
  • Perez-Gomez, Beatriz
  • Gómez-Acebo, Inés
  • Oliete-Canela, Anna
  • Diéguez-Rodríguez, Marta
  • Tusquets, Ignasi
  • Amiano, Pilar
  • Mengual, Lourdes
  • Ardanaz, Eva
  • Capelo, Rocío
  • Molina de la Torre, Antonio J
  • Salas-Trejo, Dolores
  • Fernández-Tardón, Guillermo
  • Lope Carvajal, Virginia
  • Jimenez-Moleon, Jose J.
  • Marcos-Gragera, Rafael
  • Dierssen-Sotos, Trinidad
  • Azpiri, Mikel
  • Muñoz, Montse
  • Guevara, Marcela
  • Fernández-Villa, Tania
  • Molina-Barceló, Ana
  • Aragones, Nuria
  • Pollan-Santamaria, Marina
  • Castaño-Vinyals, Gemma
  • Alguacil, Juan
  • Kogevinas, Manolis
  • de Sanjose, Silvia
  • Costas, Laura
BACKGROUND: Alkylphenolic compounds are chemicals with endocrine disrupting properties that have been widely used in industry with important changes in their usage over time. Few epidemiologic studies have evaluated the effect of alkylphenolic compounds on human health. OBJECTIVES: We investigated whether occupational exposure to alkylphenolic compounds is associated with breast and prostate cancer. METHODS: We carried out a population-based case-control study including 1513 incident cases of breast cancer, 1095 of prostate cancer, and 3055 controls, frequency matched by sex, age and region. Occupational exposure to alkylphenolic compounds was estimated using a recently developed job-exposure matrix, which considered different scenarios of exposure and different subtypes of alkylphenolic compounds. RESULTS: History of occupational exposure to alkylphenolic compounds was modestly associated with breast cancer (OR = 1.23; 95% CI = 1.01-1.48). Within the different scenarios, the occupational use of domestic tensioactives was positively associated with breast cancer (OR = 1.28; 95% CI = 1.02-1.60), while occupational exposure in other scenarios showed mostly a suggestion of a similar positive associations. Exposure to nonylphenol ethoxylates was positively associated with breast cancer (OR = 1.21; 95% CI = 1.00-1.47), while exposure to other compounds was uncommon. In general, we did not observe associations between alkylphenolic compounds and prostate cancer, except for a positive association among men occupationally exposed to cosmetic, hair and personal hygiene products. CONCLUSIONS: Our findings suggest a modest association between breast cancer risk and occupational exposure to alkylphenolic compounds, and no associations between these compounds and prostate cancer risk. These findings warrant further corroboration in other studies.
Repisalud
Publication Artículo científico (JournalArticle)

Agreement among Mediterranean Diet Pattern Adherence Indexes: MCC-Spain Study

  • Olmedo-Requena, Rocío
  • González-Donquiles, Carmen
  • Dávila-Batista, Verónica
  • Romaguera, Dora
  • Castelló Pastor, Adela
  • Molina de la Torre, Antonio José
  • Amiano, Pilar
  • Dierssen-Sotos, Trinidad
  • Guevara, Marcela
  • Fernández-Tardón, Guillermo
  • Lozano-Lorca, Macarena
  • Alguacil, Juan
  • Peiró, Rosana
  • Huerta, José María
  • Gràcia-Lavedan, Esther
  • Aragones, Nuria
  • Fernández-Villa, Tania
  • Solans, Marta
  • Gómez-Acebo, Inés
  • Castaño-Vinyals, Gemma
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Martín, Vicente
There are many different methods used to measure the degree of adherence to a Mediterranean diet (MD), limiting comparison and interpretation of their results. The concordance between different methodologies has been questioned and their evaluation recommended. The aim of this study was to evaluate the agreement among five indexes that measure adherence to a Mediterranean dietary pattern. The study population included healthy adults selected in the Multi-Case Control Spain (MCC-Spain) study recruited in 12 provinces. A total of 3640 controls were matched to cases by age and sex. To reach the aim, the following scores of adherence to a Mediterranean dietary pattern were calculated: Mediterranean diet score (MDS), alternative Mediterranean diet (aMED), relative Mediterranean diet (rMED), dietary score (DS) and literature-based adherence score (LBAS). The relative frequency of subjects with a high level of adherence to a MD varied from 22% (aMED index) to 37.2% (DS index). Similarly, a high variability was observed for the prevalence of a low level of MD: from 24% (rMED) to 38.4% (aMED). The correlation among MDS, aMED and rMED indexes was moderate, except for MDS and aMED with a high coefficient of correlation 0.75 (95% CI 0.74⁻0.77). The Cohen's Kappa coefficient among indexes showed a moderate⁻fair concordance, except for MDS and aMED with a 0.56 (95% CI 0.55⁻0.59) and 0.67 (95% CI 0.66⁻0.68) using linear and quadratic weighting, respectively. The existing MD adherence indexes measured the same, although they were based on different constructing algorithms and varied in the food groups included, leading to a different classification of subjects. Therefore, concordance between these indexes was moderate or low.
Repisalud
Publication Artículo científico (JournalArticle)

Dietary Constituents: Relationship with Breast Cancer Prognostic (MCC-SPAIN Follow-Up)

  • Dierssen-Sotos, Trinidad
  • Gómez-Acebo, Inés
  • Gutiérrez-Ruiz, Nuria
  • Aragones, Nuria
  • Amiano, Pilar
  • Molina de la Torre, Antonio José
  • Guevara, Marcela
  • Alonso-Molero, Jéssica
  • Obón-Santacana, Mireia
  • Fernández-Tardón, Guillermo
  • Molina-Barceló, Ana
  • Alguacil, Juan
  • Marcos-Gragera, Rafael
  • Rodríguez-Cundín, Paz
  • Castaño-Vinyals, Gemma
  • Canseco Fernandez, Rosario
  • Castilla Catalán, Jesús
  • Molinuevo, Amaia
  • Perez-Gomez, Beatriz
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
The aim of this study was to characterize the relationship between the intake of the major nutrients and prognosis in breast cancer. A cohort based on 1350 women with invasive (stage I-IV) breast cancer (BC) was followed up. Information about their dietary habits before diagnosis was collected using a semi-quantitative Food Frequency Questionnaire. Participants without FFQ or with implausible energy intake were excluded. The total amount consumed of each nutrient (Kcal/day) was divided into tertiles, considering as "high intakes" those above third tertile. The main effect studied was overall survival. Cox regression was used to assess the association between death and nutrient intake. During a median follow-up of 6.5 years, 171 deaths were observed. None of the nutrients analysed was associated with mortality in the whole sample. However, in normal-weight women (BMI 18.5-25 kg/m2) a high intake of carbohydrates (≥809 Kcal/day), specifically monosaccharides (≥468 Kcal/day), worsened prognostic compared to lowest (≤352 Kcal/day). Hazard Ratios (HRs) for increasing tertiles of intake were HR:2.22 95% CI (1.04 to 4.72) and HR:2.59 95% CI (1.04 to 6.48), respectively (p trend = 0.04)). Conversely, high intakes of polyunsaturated fats (≥135 Kcal/day) improved global survival (HR: 0.39 95% CI (0.15 to 1.02) p-trend = 0.05) compared to the lowest (≤92.8 kcal/day). In addition, a protective effect was found substituting 100 kcal of carbohydrates with 100 kcal of fats in normal-weight women (HR: 0.76 95% CI (0.59 to 0.98)). Likewise, in premenopausal women a high intake of fats (≥811 Kcal/day) showed a protective effect (HR:0.20 95% CI (0.04 to 0.98) p trend = 0.06). Finally, in Estrogen Receptors (ER) negative tumors, we found a protective effect of high intake of animal proteins (≥238 Kcal/day, HR: 0.24 95% CI (0.06 to 0.98). According to our results, menopausal status, BMI and ER status could play a role in the relationship between diet and BC survival and must be taken into account when studying the influence of different nutrients.
Repisalud
Publication Artículo científico (JournalArticle)

The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study

  • Gómez-Acebo, Inés
  • Dierssen-Sotos, Trinidad
  • Palazuelos, Camilo
  • Perez-Gomez, Beatriz
  • Lope Carvajal, Virginia
  • Tusquets, Ignasi
  • Alonso, María Henar
  • Moreno, Victor
  • Amiano, Pilar
  • Molina de la Torre, Antonio José
  • Barricarte, Aurelio
  • Tardón, Adonina
  • Camacho, Antonio
  • Peiró-Pérez, Rosana
  • Marcos-Gragera, Rafael
  • Muñoz, Montse
  • Michelena-Echeveste, Maria Jesus
  • Ortega Valin, Luis
  • Guevara, Marcela
  • Castaño-Vinyals, Gemma
  • Aragones, Nuria
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
INTRODUCTION: The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers. METHODS: In this case-control study, we report the antihypertensive drugs-breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women's characteristics (i.e., menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs. RESULTS: The relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the OR increased significantly in the group with BMI ≥ 25 (OR 2.54, 95% CI, 1.24 to 5.22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to 9.05; OR for Erbb2+ cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk. CONCLUSIONS: In this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women).
Repisalud
Publication Artículo científico (JournalArticle)

Risk Model for Colorectal Cancer in Spanish Population Using Environmental and Genetic Factors: Results from the MCC-Spain study

  • Ibáñez-Sanz, Gemma
  • Díez-Villanueva, Anna
  • Alonso, María Henar
  • Rodríguez-Moranta, Francisco
  • Perez-Gomez, Beatriz
  • Bustamante, Mariona
  • Martín, Vicente
  • Llorca, Javier
  • Amiano, Pilar
  • Ardanaz, Eva
  • Tardón, Adonina
  • Jimenez-Moleon, Jose J.
  • Peiró, Rosana
  • Alguacil, Juan
  • Navarro Rivas, Carmen
  • Guinó, Elisabet
  • Binefa, Gemma
  • Fernandez-Navarro, Pablo L
  • Espinosa, Anna
  • Dávila-Batista, Verónica
  • Molina, Antonio José
  • Palazuelos, Camilo
  • Castaño-Vinyals, Gemma
  • Aragones, Nuria
  • Kogevinas, Manolis
  • Moreno, Victor
  • Pollan-Santamaria, Marina
Colorectal cancer (CRC) screening of the average risk population is only indicated according to age. We aim to elaborate a model to stratify the risk of CRC by incorporating environmental data and single nucleotide polymorphisms (SNP). The MCC-Spain case-control study included 1336 CRC cases and 2744 controls. Subjects were interviewed on lifestyle factors, family and medical history. Twenty-one CRC susceptibility SNPs were genotyped. The environmental risk model, which included alcohol consumption, obesity, physical activity, red meat and vegetable consumption, and nonsteroidal anti-inflammatory drug use, contributed to CRC with an average per factor OR of 1.36 (95% CI 1.27 to 1.45). Family history of CRC contributed an OR of 2.25 (95% CI 1.87 to 2.72), and each additional SNP contributed an OR of 1.07 (95% CI 1.04 to 1.10). The risk of subjects with more than 25 risk alleles (5th quintile) was 82% higher (OR 1.82, 95% CI 1.11 to 2.98) than subjects with less than 19 alleles (1st quintile). This risk model, with an AUROC curve of 0.63 (95% CI 0.60 to 0.66), could be useful to stratify individuals. Environmental factors had more weight than the genetic score, which should be considered to encourage patients to achieve a healthier lifestyle.
Repisalud
Publication Artículo científico (JournalArticle)

Quality of Life in a Cohort of 1078 Women Diagnosed with Breast Cancer in Spain: 7-Year Follow-Up Results in the MCC-Spain Study

  • Alonso-Molero, Jéssica
  • Dierssen-Sotos, Trinidad
  • Gómez-Acebo, Inés
  • Fernandez de Larrea-Baz, Nerea
  • Guevara, Marcela
  • Amiano, Pilar
  • Castaño-Vinyals, Gemma
  • Fernández-Villa, Tania
  • Moreno, Victor
  • Bayo, Juan
  • Molina-Barceló, Ana
  • Fernández-Ortíz, María
  • Suarez-Calleja, Claudia
  • Marcos-Gragera, Rafael
  • Castells, Xavier
  • Gil-Majuelo, Leire
  • Ardanaz, Eva
  • Perez-Gomez, Beatriz
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
Breast cancer is the most frequent cause of tumors and net survival is increasing. Achieving a higher survival probability reinforces the importance of studying health-related quality of life (HR-QoL). The main aim of this work is to test the relationship between different sociodemographic, clinical and tumor-intrinsic characteristics, and treatment received with HR-QoL measured using SF-12 and the FACT/NCCN (National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy) Breast Symptom Index (FBSI). Women with breast cancer recruited between 2008 and 2013 and followed-up until 2017-2018 in a prospective cohort answered two HR-QoL surveys: the SF-12 and FBSI. The scores obtained were related to woman and tumor characteristics using linear regression models. The telephone survey was answered by 1078 women out of 1685 with medical record follow-up (64%). Increases in all three HR-QoL scores were associated with higher educational level. The score differences between women with university qualifications and women with no schooling were 5.43 for PCS-12, 6.13 for MCS-12 and 4.29 for FBSI. Histological grade at diagnosis and recurrence in the follow-up displayed a significant association with mental and physical HR-QoL, respectively. First-line treatment received was not associated with HR-QoL scores. On the other hand, most tumor characteristics were not associated with HR-QoL. As breast cancer survival is improving, further studies are needed to ascertain if these differences still hold in the long run.
Repisalud
Publication Artículo científico (JournalArticle)

Flavonoids and the Risk of Gastric Cancer: An Exploratory Case-Control Study in the MCC-Spain Study

  • Vitelli-Storelli, Facundo
  • Molina, Antonio José
  • Zamora-Ros, Raúl
  • Fernández-Villa, Tania
  • Roussou, Vasiliki
  • Romaguera, Dora
  • Aragones, Nuria
  • Obón-Santacana, Mireia
  • Guevara, Marcela
  • Gómez-Acebo, Inés
  • Fernández-Tardón, Guillermo
  • Molina-Barceló, Ana
  • Olmedo-Requena, Rocío
  • Capelo, Rocío
  • Chirlaque, María-Dolores
  • Perez-Gomez, Beatriz
  • Moreno, Victor
  • Castilla Catalán, Jesús
  • Rubín-García, María
  • Pollan-Santamaria, Marina
  • Kogevinas, Manolis
  • Lera, Juan Pablo Barrio
  • Martín, Vicente
Several epidemiological studies have investigated the association between the dietary flavonoid intake and gastric cancer (GC) risk; however, the results remain inconclusive. Investigating the relationship between the different classes of flavonoids and the histological types and origin of GC can be of interest to the research community. We used data from a population-based multi-case control study (MCC-Spain) obtained from 12 different regions of Spain. 2700 controls and 329 GC cases were included in this study. Odds ratios (ORs) were calculated using the mixed effects logistic regression considering quartiles of flavonoid intakes and log2. Flavonoid intake was associated with a lower GC risk (ORlog2 = 0.76; 95% CI = 0.65-0.89; ORq4vsq1 = 0.60; 95%CI = 0.40-0.89; ptrend = 0.007). Inverse and statistically significant associations were observed with anthocyanidins, chalcones, dihydroflavonols and flavan-3-ols. The isoflavanoid intake was positively associated with higher cancer risk, but without reaching a statistical significance. In general, no differences were observed in the GC risk according to the location and histological type. The flavonoid intake seems to be a protective factor against GC within the MCC-study. This effect may vary depending on the flavonoid class but not by the histological type and location of the tumor. Broader studies with larger sample size and greater geographical variability are necessary.
Repisalud
Publication Artículo científico (JournalArticle)

The RS4939827 polymorphism in the SMAD7 GENE and its association with Mediterranean diet in colorectal carcinogenesis

  • Alonso-Molero, Jéssica
  • González-Donquiles, Carmen
  • Palazuelos, Camilo
  • Fernández-Villa, Tania
  • Ramos, Elena
  • Pollan-Santamaria, Marina
  • Aragones, Nuria
  • Llorca, Javier
  • Henar Alonso, M.
  • Tardón, Adonina
  • Amiano, Pilar
  • Jimenez-Moleon, Jose J.
  • Peiró Pérez, Rosana
  • Capelo, Rocío
  • Molina, Antonio J
  • Acebo, Ines Gomez
  • Guevara, Marcela
  • Perez-Gomez, Beatriz
  • Lope Carvajal, Virginia
  • Huerta, José María
  • Castaño-Vinyals, Gemma
  • Kogevinas, Manolis
  • Moreno, Victor
  • Martín, Vicente
BACKGROUND: The objective of our investigation is to study the relationship between the rs4939827 SNP in the SMAD7 gene, Mediterranean diet pattern and the risk of colorectal cancer. METHODS: We examined 1087 cases of colorectal cancer and 2409 population controls with available DNA samples from the MCC-Spain study, 2008-2012. Descriptive statistical analyses, and multivariate logistic mixed models were performed. The potential synergistic effect of rs4939827 and the Mediterranean diet pattern was evaluated with logistic regression in different strata of of adherence to the Mediterranean diet and the genotype. RESULTS: High adherence to Mediterrenean diet was statistically significantly associated with colorectal cancer risk. A decreased risk for CRC cancer was observed for the CC compared to the TT genotype (OR = 0.65 and 95% CI = 0.51-0.81) of the rs4939827 SNP Also, we could show an association between the Mediterranean diet pattern (protective factor) and rs4939827. Although the decreased risk for the CC genotype was slightly more pronounced in subjects with high adherence to Mediterrenean diet, there was no statistically significant synergistic effect between genotype CC and adherence to the Mediterranean dietary pattern factors. CONCLUSION: The SMAD7 gene and specifically the allele C could be protective for colorectal cancer. An independent protective association was also observed between high adherence Mediterranean diet pattern and CRC risk. Findings form this study indicate that high adherence to Mediterranean diet pattern has a protective role for CRC cancer probably involving the Tumor Growth Factor- β pathway in this cancer.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Biocompatibility and internalization assessment of bare and functionalised mesoporous silica nanoparticles

  • Garrido-Cano, Iris
  • Herrera, Guadalupe
  • Cejalvo, Juan Miguel
  • Lluch, Ana
  • Eroles, Pilar
  • Candela-Noguera, Vicente
  • Marcos Martínez, María Dolores|||0000-0001-7079-8589
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] We report herein an evaluation of the effect of several mesoporous silica nanoparticles (MSNs) on the cellular uptake and in vitro cytotoxicity in human cells. Bare MSNs and MSNs functionalized with polyethylene glycol or hyaluronic acid are employed to evaluate uptake efficiency and mechanisms of endocytosis in cancer (MDA-MB-231) and non-cancer (MCF10A) cells. Moreover, changes in viability, cell cycle, oxidative stress, and mitochondrial membrane potential are evaluated. Our results confirm that MSNs are internalized efficiently by human cells and that uptake mechanisms differ for cell types and particles. We also confirm that MSNs are biocompatible materials that do not induce ROS/RNS production, nor changes on mitochondrial membrane potential or cell cycle., The authors want to thank the Spanish Government RTI2018-100910-B-C41 (MCUI/AEI/FEDER, UE) and PI18/01219 (ISCIII), the Generalitat Valenciana (PROMETEO/2018/024 and ACIF/2016/030), and CIBER-BBN (CB07/01/2012) and CIBER-ONC (CB16/12/00481) for support.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer

  • Adam-Artigues, Anna
  • Garrido-Cano, Iris
  • Carbonell-Asins, Juan Antonio
  • Lameirinhas, Ana
  • Simón, Soraya
  • Ortega-Morillo, Belén
  • Martínez, María Teresa
  • Hernando, Cristina
  • Constâncio, Vera
  • Burgues, Octavio
  • Bermejo, Begoña
  • Henrique, Rui
  • Lluch, Ana
  • Jerónimo, Carmen
  • Eroles, Pilar
  • Cejalvo, Juan Miguel
[EN] The early diagnosis of breast cancer is essential to improve patients' survival rate. In this context, microRNAs have been described as potential diagnostic biomarkers for breast cancer. Particularly, circulating microRNAs have a strong value as non-invasive biomarkers. Herein, we assessed the potential of a microRNA signature based on miR-30b-5p and miR-99a-5p levels in plasma as a diagnostic biomarker for breast cancer. This two-microRNA signature was constructed by Principal Component Analysis and its prognostic value was assessed in a discovery cohort and blindly validated in a second cohort from an independent institution. ROC curve analysis and biomarker performance parameter evaluation demonstrated that our proposed signature presents a high value as a non-invasive biomarker for very early detection of breast cancer. In addition, pathway enrichment analysis identified three of the well-known pathways involved in cancer as targets of the two microRNAs., This study was financed by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) and FEDER funds (PI18/01219 to P.E. and CB16/12/00481 to A.Ll.) and from the Research Centre of the Portuguese Oncology Institute of Porto (PI 74-CBEG-CI-IPOP-19-2015 to C.J.). A.A.-A. and A.L. were funded by Asociación Española Contra el Cáncer (PRDVA18013LLUC and PRDVA19016LAME). V.C. was funded by Liga Portuguesa Contra o Cancro/Fundação PT. J.M.C. was funded by Sociedad Española de Oncología Médica (Río Hortega-SEOM). The authors are grateful to INCLIVA Biobank (PT17/0015/0049; B.000768 ISCIII) and Valencian Biobanking Network integrated into the Spanish National Biobanks Network and nursing staff from all institutions for collaboration.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies

  • Garrido-Cano, Iris
  • Adam-Artigues, Anna
  • Lameirinhas, Ana
  • Blandez, Juan F.
  • Rojo, Federico
  • Zazo, Sandra
  • Madoz-Gúrpide, Juan
  • Lluch, Ana
  • Bermejo, Begoña
  • Cejalvo, Juan Miguel
  • Eroles, Pilar
  • Candela-Noguera, Vicente
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
This work was supported by Spanish Government and cofinanced by FEDER Funds (PI18/01219, PI21/01351, PI18/00382, and RTI2018-100910-B-C41), CIBERBBN (CB07/01/2012), CIBERONC (CB16/12/00481) and the Generalitat Valenciana (project PROMETEO 2018/024). I.G.-C. was funded by Generalitat Valenciana (ACIF/2016/030), A.A. and A.L. were funded by Asociación Española Contra el Cancer. J.F.B., was funded by Instituto de Salud Carlos III and the European Social Fund for the financial support Sara Borrell (CD19/00038), V.C.-N., was funded by Ministerio de Ciencia e Innovación (FPU grant), and J.M.C. was funded by Sociedad Española de Oncología Médica (Río Hortega-SEOM). We are especially grateful to the associations Amunt Contra el Cáncer, Asociación de la Lucha Contra el Cáncer de Montesa, and Corazón Solidario Contra el Cáncer. Funding for open access charge: Universitat Politècnica de València.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy

  • Garrido-Cano, Iris
  • Adam-Artigues, Anna
  • Lameirinhas, Ana
  • Blandez, Juan F.
  • Lluch, Ana
  • Bermejo, Begoña
  • Cejalvo, Juan Miguel
  • Eroles, Pilar
  • Candela-Noguera, Vicente
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Despite advancesin breast cancer treatment, it remainsthe leadingcause of cancer-related death in women worldwide. In this context,microRNAs have emerged as potential therapeutic targets but stillpresent some limitations for in vivo applications.Particularly, miR-200c-3p is a well-known tumor suppressor microRNAthat inhibits tumor progression and metastasis in breast cancer throughdownregulating ZEB1 and ZEB2. Basedon the above, we describe the design and validation of a nanodeviceusing mesoporous silica nanoparticles for miR-200c-3p delivery forbreast cancer treatment. We demonstrate the biocompatibility of thesynthesized nanodevices as well as their ability to escape from endosomes/lysosomesand inhibit tumorigenesis, invasion, migration, and proliferationof tumor cells in vitro. Moreover, tumor targetingand effective delivery of miR-200c-3p from the nanoparticles in vivo are confirmed in an orthotopic breast cancer mousemodel, and the therapeutic efficacy is also evidenced by a decreasein tumor size and lung metastasis, while showing no signs of toxicity.Overall, our results provide evidence that miR-200c-3p-loaded nanoparticlesare a potential strategy for breast cancer therapy and a safe andeffective system for tumor-targeted delivery of microRNAs., This research was supported by project PID2021-126304OB-C41 funded by MCIN/AEI/10.13039/501100011033/ and by European Regional Development Fund A way of doing Europe. Also, this study forms part of the Advanced Materials program (MFA/2022/049) and was supported by MCIN with funding from European Union NextGeneration EU(PRTR-C17.I1) and by Generalitat Valenciana. This study was also supported by Generalitat Valenciana (CIPROM/2021/007). This research was also supported by CIBER Consorcio Centro de Investigación Biomédica en Red CIBER-BBN(CB07/01/2012), CIBERONC(CB16/12/00481), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación. This work was also supported by Spanish Government and cofinanced by FEDER Funds (PI18/01219, PI21/01351) .I.G.-C. was funded by Margarita Salas post doctoral grant (European Union-Nextgeneration EU). A.A.-A. and A.L. were funded by Asociación Española Contra el Cancer.J.F.B. was funded by Instituto de Salud Carlos III and the European Social Fund for the financial support 'Sara Borrell' (CD19/00038). V.C.-N. was funded by Ministerio de Ciencia e Innovacio¿n (FPU grant), and J.M.C. was funded by Sociedad Española de Oncología Médica (Río Hortega-SEOM)
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease

  • Gervas-Arruga, J.
  • Cebolla, J.J.
  • De Blas, I.
  • Roca, M.
  • Pocovi, M.
  • Giraldo, P.
Gaucher disease, the most common lysosomal storage disorder, is caused by ß-glucocerebrosidase deficiency. Bone complications are the major cause of morbidity in patients with type 1 Gaucher disease (GD1). Genetic components strongly influence bone remodelling. In addition, chronic inflammation produced by Gaucher cells induces the production of several cytokines, which leads to direct changes in the bone remodelling process and can also affect the process indirectly through other immune cells. In this study, we analysed the association between bone mineral density (BMD), bone marrow burden score, and relevant genetic polymorphisms related to bone metabolism, as well as profiles of proinflammatory cytokines in a GD1 cohort. This study included 83 patients distributed according to bone status. BMD was measured with DXA and broadband ultrasound attenuation; bone marrow involvement was evaluated using MRI. We also analysed 26 SNPs located in 14 genes related to bone metabolism. To assess proinflammatory status, we analysed IL-4, IL-6, IL-7, IL-10, IL-13, MIP-1a, MIP-1ß, and TNFa in plasma samples from 71 control participants and GD1 patients. SNP genotype proportions and BMD differed significantly between ESRI c.453-397T>C and VDR c.1024+283G>A variants. We also observed significant associations between GD1 genotypes and bone affectation. When patients were stratified by spleen status, we observed significant correlations between non-/splenectomized groups and Spanish MRI (S-MRI) score. Across genotype proportions of non-/splenectomized patients and S-MRI, we observed significant differences in ESRI c.453-397T>C, VDR c.-83-25988G>A, and TNFRSF11B c.9C>G polymorphisms. We observed different significant proinflammatory profiles between control participants, treatment-naive patients, and patients on enzyme replacement therapy (ERT); between non-/splenectomized patients (between untreated and ERT-treated patients) and among those with differing GBA genotypes. The data suggest that patients with GD1 have increased susceptibility to developing bone disease owing to the coexistence of genetic variants, and that genetic background in GD1 is fundamental to regulate the impact of proinflammatory status on the development of bone disease.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Assessment of plasma chitotriosidase activity, CCL18/PARC concentration and NP-C suspicion index in the diagnosis of Niemann-Pick disease type C: A prospective observational study

  • Castro-Orós, I.
  • Irún, P.
  • Cebolla, J.J.
  • Rodriguez-Sureda, V.
  • Mallén, M.
  • Pueyo, M.J.
  • Mozas, P.
  • Dominguez, C.
  • Pocoví, M.
  • Bustamante, A.
  • Ortega, I.P.
  • Rivera, P.M.
  • Palomino, A.
  • Caceres, M.
  • Maestre, S.J.
  • Calderon, E.
  • Uranga, J.J.R.
  • Lorite, J.B.
  • Bustos, M.D.G.
  • Moreno, J.M.G.
  • Gonzalez, T.B.
  • Muñoz, A.
  • Acebal, M.R.
  • Medina, R.C.
  • Nieto, J.S.
  • Nuñez, E.
  • Sierra, C.
  • Campos, M.G.
  • Fernández de la Puebla, F.
  • Sepulveda, J.J.O.
  • Laso, E.L.
  • Maestre, A.
  • Martos, M.L.
  • Zafra, P.
  • Rosso, S.P.
  • Rosso, R.E.
  • Reyes, M.J.S.
  • Fernandez, L.A.
  • Moreno, A.O.
  • Pardo, C.C.
  • Martin, A.
  • Poveda, J.A.
  • Cantero, B.N.
  • Ruiz, P.G.
  • Rodrigo, M.
  • Posada, I.
  • Ferro, A.S.
  • Jesús, Hernandez Gallego
  • Villarejo, A.
  • San Martin, A.O.H.
  • Perez, A.G.
  • de Rivera, F.J.R.
  • Sanz, I.
  • Santos, F.
  • Gutierrez-Solana, L.
  • Fontan, C.
  • Duque, S.C.
  • Leal, R.M.
  • Gamez, J.
  • Santamaria, E.
  • del Toro, M.
  • Delgado, T.
  • Lorente, I.
  • Lleó, A.
  • Pagonabarraga, J.
  • Calvet, M.S.
  • Turón, E.
  • Moliner, E.
  • Pascual, B.
  • Almenar, C.
  • Torralba, A.O.
  • Floriach, R.M.
  • Nilda, Venegas Bernal
  • Villegas, M.D.L.
  • Giné, L.P.
  • Nomdedeu, B.
  • Martí, M.J.
  • Domenech, M.T.B.
  • Gascón, J.
  • Costa, J.
  • Fons, C.
  • Pineda, M.
  • Vidal, M.T.A.
  • Mira, E.
  • Tartari, J.P.
  • Aparici, R.C.
  • Sanchez, A.A.
  • Codony, M.B.
  • Alberti, M.A.
  • Ripoll, G.P.
  • Modol, R.
  • Genis, D.
  • Sivera, R.
  • Costa, J.F.V.
  • Martinez, I.
  • Smeyers, P.
  • Vila, T.
  • Casanova, B.
  • Miralles, F.C.P.
  • Serra, J.D.
  • Miñana, I.V.
  • Merino, C.V.
  • Garcia, R.
  • Jorda, R.M.S.
  • Clavel, J.
  • Santana, C.L.
  • Capablo, J.L.
  • Gazulla, J.
  • Padilla, P.
  • Loureiro, C.
  • Fdez-Balbuen, C.
  • Arias, M.
  • Rabuñal, M.J.
  • Sobrido, M.J.
  • Cia, M.T.
  • Yoldi, M.E.
  • Erro, M.E.
  • Fontes, A.
  • Axpe, I.R.
  • Sasieta, F.J.E.
  • Carlos, J.
  • Esteban, G.
  • Muñoz, J.A.S.
  • Espinosa, N.R.
  • Hernandez, M.A.
  • Martin, I.T.
  • Garrido, A.F.
  • Aporta, R.
  • Domingo, R.
  • Naranjo, I.C.
  • Gomez, M.A.R.
  • Ferrer, G.A.
Background: Niemann-Pick disease type C (NP-C) is a rare, autosomal recessive neurodegenerative disease caused by mutations in either the NPC1 or NPC2 genes. The diagnosis of NP-C remains challenging due to the non-specific, heterogeneous nature of signs/symptoms. This study assessed the utility of plasma chitotriosidase (ChT) and Chemokine (C-C motif) ligand 18 (CCL18)/pulmonary and activation-regulated chemokine (PARC) in conjunction with the NP-C suspicion index (NP-C SI) for guiding confirmatory laboratory testing in patients with suspected NP-C. Methods: In a prospective observational cohort study, incorporating a retrospective determination of NP-C SI scores, two different diagnostic approaches were applied in two separate groups of unrelated patients from 51 Spanish medical centers (n = 118 in both groups). From Jan 2010 to Apr 2012 (Period 1), patients with =2 clinical signs/symptoms of NP-C were considered ''suspected NP-C'' cases, and NPC1/NPC2 sequencing, plasma chitotriosidase (ChT), CCL18/PARC and sphingomyelinase levels were assessed. Based on findings in Period 1, plasma ChT and CCL18/PARC, and NP-C SI prediction scores were determined in a second group of patients between May 2012 and Apr 2014 (Period 2), and NPC1 and NPC2 were sequenced only in those with elevated ChT and/or elevated CCL18/PARC and/or NP-C SI =70. Filipin staining and 7-ketocholesterol (7-KC) measurements were performed in all patients with NP-C gene mutations, where possible. Results: In total across Periods 1 and 2, 10/236 (4%) patients had a confirmed diagnosis o NP-C based on gene sequencing (5/118 4.2%] in each Period): all of these patients had two causal NPC1 mutations. Single mutant NPC1 alleles were detected in 8/236 (3%) patients, overall. Positive filipin staining results comprised three classical and five variant biochemical phenotypes. No NPC2 mutations were detected. All patients with NPC1 mutations had high ChT activity, high CCL18/PARC concentrations and/or NP-C SI scores =70. Plasma 7-KC was higher than control cut-off values in all patients with two NPC1 mutations, and in the majority of patients with single mutations. Family studies identified three further NP-C patients. Conclusion: This approach may be very useful for laboratories that do not have mass spectrometry facilities and therefore, they cannot use other NP-C biomarkers for diagnosis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease

  • Andrade-Campos, M.
  • Alfonso, P.
  • Irun, P.
  • Armstrong, J.
  • Calvo, C.
  • Dalmau, J.
  • Domingo, M.R.
  • Barbera, J.L.
  • Cano, H.
  • Fernandez-Galán, M.A.
  • Franco, R.
  • Gracia, I.
  • Gracia-Antequera, M.
  • Ibañez, A.
  • Lendinez, F.
  • Madruga, M.
  • Martin-Hernández, E.
  • O''Callaghan, M.D.M.
  • Del Soto, A.P.
  • Del Prado, Y.R.
  • Sancho-Val, I.
  • Sanjurjo, P.
  • Pocovi, M.
  • Giraldo, P.
Background: The enzymatic replacement therapy (ERT) availability for Gaucher disease (GD) has changed the landscape of the disease, several countries have screening programs. These actions have promoted the early diagnosis and avoided many complications in pediatric patients. In Spain ERT has been available since 1993 and 386 patients have been included in the Spanish Registry of Gaucher Disease (SpRGD). The aim of this study is to analyze the impact of ERT on the characteristics at time of diagnosis and initial complications in pediatric Gaucher disease patients. Aim: To analyze the impact of ERT on the characteristics at time of diagnosis and initial complications in pediatric Gaucher disease patients. Methods: A review of data in SpRGD from patients'' diagnosed before 18 years old was performed. The cohort was split according the year of diagnosis (=1994, cohort A; =1995, cohort B). Results: A total of 98 pediatric patients were included, GD1: 80, GD3: 18; mean age: 7.2 (0.17-16.5) years, 58 (59.2%) males and 40 (40.8%) females. Forty-five were diagnosed = 1994 and 53 = 1995. Genotype: N370S/N370S: 2 (2.0%), N370S/L444P: 27 (27.5%), N370S/other: 47 (48%), L444P/L444P: 7 (7.1%), L444P/D409H: 2 (2.0%), L444P/other: 3 (6.2%), other/other: 10 (10.2%). The mean age at diagnosis was earlier in patients diagnosed after 1995 (p < 0.001) and different between the subtypes, GD1: 8.2 (0.2-16.5) years and GD3: 2.8 (0.17-10.2) years (p < 0.001). There were more severe patients in the group diagnosed before 1994 (p = 0.045) carrying L444P (2), D409H (2), G377S (1), G195W (1) or the recombinant mutation. The patients'' diagnosed =1994 showed worse cytopenias, higher chance of bone vascular complications at diagnosis and previous spleen removal. The patients started ERT at a median time after diagnosis of 5.2 years [cohort A] and 1.6 years [cohort B] (p < 0.001). Conclusions: The early diagnosis of Gaucher disease in the era of ERT availability has permitted to reduce the incidence of severe and irreversible initial complication in pediatric patients, and this has permitted better development of these patients. This is the largest pediatric cohort from a national registry.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project

  • Giraldo, P.
  • Andrade-Campos, M.
  • Alfonso, P.
  • Irun, P.
  • Atutxa, K.
  • Acedo, A.
  • Barez, A.
  • Blanes, M.
  • Diaz-Morant, V.
  • Fernández-Galán, M.A.
  • Franco, R.
  • Gil-Cortes, C.
  • Giner, V.
  • Ibañez, A.
  • Latre, P.
  • Loyola, I.
  • Luño, E.
  • Hernández-Martin, R.
  • Medrano-Engay, B.
  • Puerta, J.
  • Roig, I.
  • de la Serna, J.
  • Salamero, O.
  • Villalón, L.
  • Pocovi, M.
We report data from a prospective, observational study (ZAGAL) evaluating miglustat 100 mg three times daily orally. in treatment-naïve patients and patients with type 1 Gaucher Disease (GD1) switched from previous enzyme replacement therapy (ERT). Clinical evolution, changes in organ size, blood counts, disease biomarkers, bone marrow infiltration (S-MRI), bone mineral density by broadband ultrasound densitometry (BMD), safety and tolerability annual reports were analysed. Between May 2004 and April 2016, 63 patients received miglustat therapy; 20 (32%) untreated and 43 (68%) switched. At the time of this report 39 patients (14 [36%] treatment-naïve; 25 [64%] switch) remain on miglustat. With over 12-year follow-up, hematologic counts, liver and spleen volumes remained stable. In total, 80% of patients achieved current GD1 therapeutic goals. Plasma chitotriosidase activity and CCL-18/PARC concentration showed a trend towards a slight increase. Reductions on S-MRI (p = 0.042) with an increase in BMD (p < 0.01) were registered. Gastrointestinal disturbances were reported in 25/63 (40%), causing miglustat suspension in 11/63 (17.5%) cases. Thirty-eight patients (60%) experienced a fine hand tremor and two a reversible peripheral neuropathy. Overall, miglustat was effective as a long-term therapy in mild to moderate naïve and ERT stabilized patients. No unexpected safety signals were identified during 12-years follow-up.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain, the CRIVERVA study

  • Trapero Bertrán, Marta
  • Acera Pérez, Amelia
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Manresa, J. M|||0000-0001-8306-5798
  • Rodríguez Capriles, Diego
  • Rodríguez Martínez, Ana
  • Bonet Simó, Josep Maria|||0000-0002-7981-5880
  • Sánchez Sánchez, Norman
  • Hidalgo Valls, Pablo
  • Díaz Sanchís, Mireia
The aim of the study is to carry out a cost-effectiveness analysis of three different interventions to promote the uptake of screening for cervical cancer in general practice in the county of Valles Occidental, Barcelona, Spain. Women aged from 30 to 70 years (n = 15,965) were asked to attend a general practice to be screened. They were randomly allocated to one of four groups: no intervention group (NIG); one group where women received an invitation letter to participate in the screening (IG1); one group where women received an invitation letter and informative leaflet (IG2); and one group where women received an invitation letter, an informative leaflet and a phone call reminder (IG3). Clinical effectiveness was measured as the percentage increase in screening coverage. A cost-effectiveness analysis was performed from the perspective of the public health system with a time horizon of three to five years - the duration of the randomised controlled clinical trial. In addition, a deterministic sensitivity analysis was performed. Results are presented according to different age groups. The incremental cost-effectiveness ratio (ICER) for the most cost-effective intervention, IG1, compared with opportunistic screening was € 2.78 per 1% increase in the screening coverage. The age interval with the worst results in terms of efficiency was women aged < 40 years. In a population like Catalonia, with around 2 million women aged 30 to 70 years and assuming that 40% of these women were not attending general practice to be screened for cervical cancer, the implementation of an intervention to increase screening coverage which consists of sending a letter would cost on average less than € 490 for every 1000 women. ClinicalTrials.gov Identifier: . The online version of this article (doi:10.1186/s12889-017-4115-0) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Risk Model for Prostate Cancer Using Environmental and Genetic Factors in the Spanish Multi-Case- Control (MCC) Study

  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Fernández-Navarro, Pablo|||0000-0001-9427-2581
  • Palazuelos, Camilo
  • Morros, Rosa|||0000-0001-6752-8748
  • Aragonés, Nuria
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Jiménez Monleón, Jose J.
  • Ruiz Cerdá, José Luis
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Ruiz-Dominguez, José Manuel
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Pollán, Marina|||0000-0002-4328-1565
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Llorca, Javier|||0000-0001-8569-861X
Prostate cancer (PCa) is the second most common cancer among men worldwide. Its etiology remains largely unknown compared to other common cancers. We have developed a risk stratification model combining environmental factors with family history and genetic susceptibility. 818 PCa cases and 1,006 healthy controls were compared. Subjects were interviewed on major lifestyle factors and family history. Fifty-six PCa susceptibility SNPs were genotyped. Risk models based on logistic regression were developed to combine environmental factors, family history and a genetic risk score. In the whole model, compared with subjects with low risk (reference category, decile 1), those carrying an intermediate risk (decile 5) had a 265% increase in PCa risk (OR = 3.65, 95% CI 2.26 to 5.91). The genetic risk score had an area under the ROC curve (AUROC) of 0.66 (95% CI 0.63 to 0.68). When adding the environmental score and family history to the genetic risk score, the AUROC increased by 0.05, reaching 0.71 (95% CI 0.69 to 0.74). Genetic susceptibility has a stronger risk value of the prediction that modifiable risk factors. While the added value of each SNP is small, the combination of 56 SNPs adds to the predictive ability of the risk model.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study

  • Peremiquel-Trillas, Paula
  • Benavente, Yolanda|||0000-0003-1422-4614
  • Martín-Bustamante, Mayte
  • Casabonne, Delphine
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Oliete-Canela, Anna
  • Diéguez-Rodríguez, Marta
  • Tusquets, Ignasi
  • Amiano, Pilar
  • Mengual, Lourdes
  • Ardanaz, Eva
  • Capelo, Rocío
  • Molina de la Torre, Antonio José
  • Salas Trejo, Dolores
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Lope, Virginia
  • Jimenez-Moleon, José J.
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Azpiri, Mikel
  • Muñoz, Montse
  • Guevara, Marcela|||0000-0001-9242-6364
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Molina-Barceló, Ana|||0000-0001-5113-6475
  • Aragonés, Nuria
  • Pollán, Marina|||0000-0002-4328-1565
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Alguacil, Juan|||0000-0003-2703-9725
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Costas, Laura
Background: Alkylphenolic compounds are chemicals with endocrine disrupting properties that have been widely used in industry with important changes in their usage over time. Few epidemiologic studies have evaluated the effect of alkylphenolic compounds on human health. Objectives: We investigated whether occupational exposure to alkylphenolic compounds is associated with breast and prostate cancer. Methods: We carried out a population-based case-control study including 1513 incident cases of breast cancer, 1095 of prostate cancer, and 3055 controls, frequency matched by sex, age and region. Occupational exposure to alkylphenolic compounds was estimated using a recently developed job-exposure matrix, which considered different scenarios of exposure and different subtypes of alkylphenolic compounds. Results: History of occupational exposure to alkylphenolic compounds was modestly associated with breast cancer (OR = 1.23; 95% CI = 1.01-1.48). Within the different scenarios, the occupational use of domestic tensioactives was positively associated with breast cancer (OR = 1.28; 95% CI = 1.02-1.60), while occupational exposure in other scenarios showed mostly a suggestion of a similar positive associations. Exposure to nonylphenol ethoxylates was positively associated with breast cancer (OR = 1.21; 95% CI = 1.00-1.47), while exposure to other compounds was uncommon. In general, we did not observe associations between alkylphenolic compounds and prostate cancer, except for a positive association among men occupationally exposed to cosmetic, hair and personal hygiene products. Conclusions: Our findings suggest a modest association between breast cancer risk and occupational exposure to alkylphenolic compounds, and no associations between these compounds and prostate cancer risk. These findings warrant further corroboration in other studies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tumour characteristics and survivorship in a cohort of breast cancer, the MCC-Spain study

  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Palazuelos-Calderón, Camilo
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Amiano, Pilar
  • Guevara, Marcela|||0000-0001-9242-6364
  • Molina de la Torre, Antonio José
  • Domingo, Laia|||0000-0003-4420-0891
  • Fernández-Ortiz, María|||0000-0003-0017-875X
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Alguacil, Juan|||0000-0003-2703-9725
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Ibáñez, Josefa
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Diaz-Santos, Marian
  • Alonso, M. Henar
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • García Palomo, Andrés|||0000-0002-9159-9025
  • Ardanaz, Eva
  • Molinuevo, Amaia
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The objective of this study is to analyse the relative survival with breast cancer in women diagnosed after new treatments were generalised and to ascertain the current effect that tumour characteristics such as grade, stage or subtype have on survival as well as the new AJCC-pathological prognostic score. The breast cancer MCC-Spain follow-up study is a prospective cohort study of 1685 incident breast cancer cases. Women between 20 and 85 years old were recruited between the years 2008 and 2013 in 18 hospitals located in 10 Spanish provinces and they have been followed until 2017/2018. Relative survival was estimated after 3, 5 and 8 years of follow-up using Ederer II method. In addition, Weibull regression adjusted by age, hospital, grade and stage was used to investigate prognosis factors. Among components of TNM staging system, tumour size greater than 50 mm (i.e. T3 or T4) more than doubled the risk of dying, while N3 nodal involvement and presence of metastasis had a huge effect on mortality. The AJCC pathological prognostic score strongly correlated with survival; thus, hazard ratios increased as the score rose, being 2.31, 4.00, 4.94, 7.92, 2.26, 14.9 and 58.9 for scores IB, IIA, IIB, IIIA, IIIB, IIIC and IV, respectively. Both TNM staging and histological/molecular biomarkers are associated with overall survival in Spanish women with breast cancer; when both are combined in the AJCC pathological prognosis score, the prognostic value improved with risk indices that increased rapidly as the pathological prognosis score increased The online version of this article (10.1007/s10549-020-05600-x) contains supplementary material, which is available to authorised users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Online Cost-Effectiveness ANalysis (OCEAN), a user-friendly interface to conduct cost-effectiveness analyses for cervical cancer

  • Moriña, David|||0000-0001-5949-7443
  • Martí, José Ignacio
  • Puig, Pedro|||0000-0002-6607-9642
  • Díaz Sanchís, Mireia
Most cost-effectiveness analyses in the context of cervical cancer prevention involve the use of mathematical models to simulate HPV infection, cervical disease and prevention strategies. However, it is common for professionals who would need to perform these analyses to not be familiar with the models. This work introduces the Online Cost-Effectiveness ANalysis tool, featuring an easy-to-use web interface providing health professionals, researchers and decision makers involved in cervical cancer prevention programmes with a useful instrument to conduct complex cost-effectiveness analyses, which are becoming an essential tool as an approach for supporting decision-making that involves important trade-offs. The users can run cost-effectiveness evaluations of cervical cancer prevention strategies without deep knowledge of the underlying mathematical model or any programming language, obtaining the most relevant costs and health outcomes in a user-friendly format. The results provided by the tool are consistent with the existing literature. Having such a tool will be an asset to the cervical cancer prevention community, providing researchers with an easy-to-use instrument to conduct cost-effectiveness analyses.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dietary Constituents, Relationship with Breast Cancer Prognostic (MCC-SPAIN Follow-Up)

  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Gutiérrez-Ruiz, Nuria
  • Aragonés, Nuria
  • Amiano, Pilar
  • Molina de la Torre, Antonio José
  • Guevara, Marcela|||0000-0001-9242-6364
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Obón-Santacana, Mireia|||0000-0003-4646-3513
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Molina-Barceló, Ana|||0000-0001-5113-6475
  • Alguacil, Juan|||0000-0003-2703-9725
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Rodríguez-Cundín, Paz
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Canseco Fernandez, Rosario
  • Castilla, Jesus|||0000-0002-6396-7265
  • Molinuevo, Amaia
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The aim of this study was to characterize the relationship between the intake of the major nutrients and prognosis in breast cancer. A cohort based on 1350 women with invasive (stage I-IV) breast cancer (BC) was followed up. Information about their dietary habits before diagnosis was collected using a semi-quantitative Food Frequency Questionnaire. Participants without FFQ or with implausible energy intake were excluded. The total amount consumed of each nutrient (Kcal/day) was divided into tertiles, considering as "high intakes" those above third tertile. The main effect studied was overall survival. Cox regression was used to assess the association between death and nutrient intake. During a median follow-up of 6.5 years, 171 deaths were observed. None of the nutrients analysed was associated with mortality in the whole sample. However, in normal-weight women (BMI 18.5-25 kg/m 2) a high intake of carbohydrates (≥809 Kcal/day), specifically monosaccharides (≥468 Kcal/day), worsened prognostic compared to lowest (≤352 Kcal/day). Hazard Ratios (HRs) for increasing tertiles of intake were HR:2.22 95% CI (1.04 to 4.72) and HR:2.59 95% CI (1.04 to 6.48), respectively (p trend = 0.04)). Conversely, high intakes of polyunsaturated fats (≥135 Kcal/day) improved global survival (HR: 0.39 95% CI (0.15 to 1.02) p -trend = 0.05) compared to the lowest (≤92.8 kcal/day). In addition, a protective effect was found substituting 100 kcal of carbohydrates with 100 kcal of fats in normal-weight women (HR: 0.76 95% CI (0.59 to 0.98)). Likewise, in premenopausal women a high intake of fats (≥811 Kcal/day) showed a protective effect (HR:0.20 95% CI (0.04 to 0.98) p trend = 0.06). Finally, in Estrogen Receptors (ER) negative tumors, we found a protective effect of high intake of animal proteins (≥238 Kcal/day, HR: 0.24 95% CI (0.06 to 0.98). According to our results, menopausal status, BMI and ER status could play a role in the relationship between diet and BC survival and must be taken into account when studying the influence of different nutrients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Validating a breast cancer score in Spanish women. The MCC-Spain study

  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Palazuelos, Camilo
  • Fernández-Navarro, Pablo|||0000-0001-9427-2581
  • Altzibar, Jone M.
  • González-Donquiles, Carmen
  • Ardanaz, Eva
  • Bustamante, Mariona|||0000-0003-0127-2860
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Vidal, Carmen|||0000-0003-2768-2710
  • Bayo-Calero, Juan
  • Tardón, Adonina|||0000-0001-5150-1209
  • Salas, Dolores|||0000-0003-0064-1222
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Morros, Rosa|||0000-0001-6752-8748
  • Rodriguez-Cundin, Paz
  • Vinyals, Gemma Castaño
  • Ederra, María
  • Vilorio-Marqués, Laura
  • Amiano, Pilar
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
A breast-risk score, published in 2016, was developed in white-American women using 92 genetic variants (GRS92), modifiable and non-modifiable risk factors. With the aim of validating the score in the Spanish population, 1,732 breast cancer cases and 1,910 controls were studied. The GRS92, modifiable and non-modifiable risk factor scores were estimated via logistic regression. SNPs without available genotyping were simulated as in the aforementioned 2016 study. The full model score was obtained by combining GRS92, modifiable and non-modifiable risk factor scores. Score performances were tested via the area under the ROC curve (AUROC), net reclassification index (NRI) and integrated discrimination improvement (IDI). Compared with non-modifiable and modifiable factor scores, GRS92 had higher discrimination power (AUROC: 0.6195, 0.5885 and 0.5214, respectively). Adding the non-modifiable factor score to GRS92 improved patient classification by 23.6% (NRI = 0.236), while the modifiable factor score only improved it by 7.2%. The full model AUROC reached 0.6244. A simulation study showed the ability of the full model for identifying women at high risk for breast cancer. In conclusion, a model combining genetic and risk factors can be used for stratifying women by their breast cancer risk, which can be applied to individualizing genetic counseling and screening recommendations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population, The MCC-Spain Study

  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Palazuelos, Camilo
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Lope, Virginia
  • Tusquets, Ignasi
  • Alonso, María Henar
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Amiano, Pilar
  • Molina de la Torre, Antonio José
  • Barricarte, Aurelio
  • Tardón, Adonina|||0000-0001-5150-1209
  • Camacho, Antonio
  • Peiro-Perez, Rosana
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Muñoz, Montse
  • Michelena-Echeveste, Maria Jesus
  • Ortega Valin, Luis
  • Guevara, Marcela|||0000-0001-9242-6364
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers. In this case-control study, we report the antihypertensive drugs-breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women's characteristics (i.e., menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs. The relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the OR increased significantly in the group with BMI ≥ 25 (OR 2.54, 95% CI, 1.24 to 5.22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to 9.05; OR for Erbb2+ cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk. In this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer, The Spanish Multi-Case-control (MCC) study

  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • de Pedro, María
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Servitja, Sonia|||0000-0001-6988-4519
  • Morros, Rosa|||0000-0001-6752-8748
  • Amiano, Pilar
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Barricarte, Aurelio
  • Tardón, Adonina|||0000-0001-5150-1209
  • Diaz-Santos, Marian
  • Peiro-Perez, Rosana
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Lope, Virginia
  • Gracia-Lavedan, Esther
  • Alonso, M. Henar
  • Michelena-Echeveste, Maria Jesus
  • García Palomo, Andrés|||0000-0002-9159-9025
  • Guevara, Marcela|||0000-0001-9242-6364
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The relationship between non-steroidal anti-inflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce attention has been paid to their effect on different tumor categories (i.e.: ductal/non-ductal, stage at diagnosis or presence of hormonal receptors). In this case-control study, we report the NSAID - breast cancer relationship in 1736 breast cancer cases and 1895 healthy controls; results are reported stratifying by the women's characteristics (i.e.: menopausal status or body mass index category) and by tumor characteristics. In our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0.76; 95 % Confidence Interval [CI]: 0.64-0.89), and similar results were found for acetic acid derivatives, propionic acid derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i.e. OR < 1), except in advanced clinical stage and triple negative cancers. Most NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to be restricted to hormone + or HER2+ cancers. The online version of this article (doi:10.1186/s12885-016-2692-4) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

  • Adam-Artigues, Anna|||0000-0002-4257-8535
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Martínez-Sabadell, Alex|||0000-0002-9477-1396
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Cervera Vidal, Raimundo|||0000-0002-8213-4058
  • Tormo, Eduardo
  • Hernando Davalillo, Cristina
  • Martínez Martínez, María Teresa|||0000-0003-1312-3555
  • Carbonell Asins, Juan Antonio|||0000-0002-8449-5674
  • Simón, Soraya
  • Poveda Ferriols, Jesús Manuel|||0000-0002-9785-0997
  • Moragón, Santiago|||0000-0001-6490-6977
  • Zazo, Sandra
  • Martínez, Débora
  • Rovira, Ana|||0000-0003-1301-2599
  • Burgués, Octavio|||0000-0002-2471-5516
  • Rojo, Federico|||0000-0001-9989-0290
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Bermejo, Begoña
  • Lluch, Ana|||0000-0003-2766-407X
  • Prat, Aleix|||0000-0003-2377-540X
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Eroles, Pilar|||0000-0003-2708-6206
  • Cejalvo, Juan Miguel|||0000-0002-8755-8626
Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of trastuzumab resistance. AXL orchestrates epithelial-to-mesenchymal transition and heterodimerizes with HER2, leading to activation of PI3K/AKT and MAPK pathways in a ligand-independent manner. Genetic depletion and pharmacological inhibition of AXL restored trastuzumab response in vitro and in vivo. AXL inhibitor plus trastuzumab achieved complete regression in trastuzumab-resistant patient-derived xenograft models. Moreover, AXL expression in HER2-positive primary tumors was able to predict prognosis. Data from the PAMELA trial showed a change in AXL expression during neoadjuvant dual HER2 blockade, supporting its role in resistance. Therefore, our study highlights the importance of targeting AXL in combination with anti-HER2 drugs across HER2-amplified breast cancer patients with high AXL expression. Furthermore, it unveils the potential value of AXL as a druggable prognostic biomarker in HER2-positive breast cancer. AXL is a prognostic biomarker and a potential therapeutic target to restore trastuzumab response in HER2 + breast cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Consumption of ultra-processed food and drinks and chronic lymphocytic leukemia in the mcc-spain study

  • Solans, Marta|||0000-0002-2397-0435
  • Fernández-Barrés, Sílvia|||0000-0002-9977-2291
  • Romaguera, Dora|||0000-0002-5762-8558
  • Benavente, Yolanda|||0000-0003-1422-4614
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Gracia-Lavedan, Esther
  • Costas, Laura
  • Robles, Claudia
  • González Barca, Eva|||0000-0002-1323-1508
  • Banda, Esmeralda de la
  • Alonso, Esther
  • Aymerich, Marta
  • Campo, Elias|||0000-0001-9850-9793
  • Llorca, Javier|||0000-0001-8569-861X
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Olmedo-Requena, Rocío|||0000-0003-0054-6700
  • Gimeno, Eva|||0000-0002-3534-6189
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Sanjose, Sílvia de
  • Amiano, Pilar
  • Casabonne, Delphine
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries. Its etiology is largely unknown but increasing incidence rates observed worldwide suggest that lifestyle and environmental factors such as diet might play a role in the development of CLL. Hence, we hypothesized that the consumption of ultra-processed food and drinks (UPF) might be associated with CLL. Data from a Spanish population-based case-control study (MCC-Spain study) including 230 CLL cases (recruited within three years of diagnosis) and 1634 population-based controls were used. The usual diet during the previous year was collected through a validated food frequency questionnaire and food and drink consumption was categorized using the NOVA classification scheme. Logistic regression models adjusted for potential confounders were used. Overall, no association was reported between the consumption of UPF and CLL cases (OR per each 10% increase of the relative contribution of UPF to total dietary intake = 1.09 (95% CI: 0.94; 1.25)), independently of the Rai stage at diagnosis. However, when analyses were restricted to cases diagnosed within <1 year (incident), each 10% increment in the consumption of UPF was associated with a 22% higher odds ratio of CLL (95% CI: 1.02, 1.47) suggesting that the overall results might be affected by the inclusion of prevalent cases, who might have changed their dietary habits after cancer diagnosis. Given the low number of cases in the subgroup analyses and multiple tests performed, chance findings cannot totally be ruled out. Nonetheless, positive associations found in CLL incident cases merit further research, ideally in well-powered studies with a prospective design.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Assessment of plasma chitotriosidase activity, CCL18/PARC concentration and NP-C suspicion index in the diagnosis of Niemann-Pick disease type C, A prospective observational study

  • De Castro-Orós, Isabel
  • Irún, Pilar|||0000-0003-3392-7200
  • Cebolla, Jorge J.|||0000-0001-8727-9179
  • Rodríguez Sureda, Víctor|||0000-0003-4942-9249
  • Mallén, Miguel
  • Pueyo, María Jesús
  • Mozas, Pilar
  • Dominguez, Carmen
  • Pocoví, Miguel
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Pérez Ortega, Irene
  • Mir, Pablo|||0000-0003-1656-302X
  • Palomino, Alfredo
  • Caceres, Maite
  • Jesús Maestre, Silvia|||0000-0002-1874-4628
  • Calderón, Enrique J.|||0000-0002-3166-5086
  • Rodríguez Uranga, Juan Jesus
  • Bautista Lorite, Juan
  • Gómez Bustos, Mª Dolores
  • García Moreno, Jose M.
  • Bermejo González, Teresa
  • Muñoz, Alfredo
  • Romero Acebal, Manuel
  • Calvo Medina, Rocío|||0000-0003-3322-4265
  • Serrano Nieto, Juliana
  • Nuñez, Esmeralda
  • Sierra, Carlos
  • Gil-Campos, Mercedes|||0000-0002-9007-0242
  • Fernández de la Puebla, Rafael
  • Ochoa Sepulveda, José
  • López Laso, Eduardo|||0000-0001-7732-6277
  • Maestre, Asunción
  • Ley Martos, Myriam|||0000-0001-8581-6786
  • Zafra, Pamela
  • Pantoja Rosso, Servando
  • Espinosa Rosso, Raul|||0000-0002-0876-8378
  • Salado Reyes, Mª Jesus
  • Arrabal Fernández, Luisa
  • Ortega Moreno, Angel
  • Carnero Pardo, C.|||0000-0003-3415-6727
  • Martin, Alejandro
  • Alom Poveda, Jordi
  • Nacimiento Cantero, Belén
  • García Ruiz, Pedro
  • Rodrigo, Maria
  • Posada, Ignacio
  • Sánchez Ferro, Alvaro
  • Hernández Gallego, Jesús
  • Villarejo-Galende, Alberto|||0000-0002-6834-7620
  • Herrero San Martin, Alejandro O.
  • García Perez, Asunción
  • Rodríguez de Rivera, Francisco Javier|||0000-0001-9008-7629
  • Sanz, Irene
  • Santos, Fernando
  • González Gutiérrez-Solana, Luis|||0000-0003-2890-4565
  • Fontan, Carmen
  • Cantero Duque, Susana
  • Martínez Leal, Rafael
  • Gamez Carbonell, Josep|||0000-0002-0426-1844
  • Santamaria, Esteve
  • Del Toro, Mireia|||0000-0002-8163-1853
  • Delgado, Tania
  • Lorente, Isabel
  • Lleó, Alberto|||0000-0002-2568-5478
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Turon Viñas, Eulalia|||0000-0001-6171-0282
  • Moliner Calderón, Elisenda|||0000-0001-5631-2888
  • Pascual Sedano, Berta María|||0000-0002-9298-8241
  • Almenar, Consuelo
  • Olivé Torralba, Anna
  • Misericordia Floriach, Robert
  • Venegas Bernal, Nilda
  • Lopez Villegas, Maria Dolores|||0000-0002-1023-1991
  • Planellas, Lluis|||0000-0002-0769-6675
  • Nomdedeu Tobella, Benet|||0000-0001-7831-4075
  • Martí Domenech, Maria Josep|||0000-0002-9872-7835
  • Bounjourno Domenech, Mª Teresa
  • Gascón, Jordi
  • Costa, Joan
  • Fons, Carmen|||0000-0001-7227-1350
  • Pineda, Mercedes
  • Abellán Vidal, Maria Teresa
  • Mira, Emili
  • Tartari, Juan Pablo
  • Castilla Aparici, Roser
  • Arévalo Sanchez, Antonio
  • Boix Codony, Marc
  • Alberti, María Antonia
  • Piñol-Ripoll, Gerard
  • Modol, Ramón
  • Genis, David
  • Sivera, Rafael|||0000-0003-2810-1180
  • Vázquez Costa, Juan Francisco
  • Martinez, Irene
  • Smeyers, Patricia
  • Vila, Tomas
  • Casanova, Bonaventura|||0000-0003-3806-925X
  • Pérez Miralles, Francisco Carlos
  • Dalmau Serra, Jaime
  • Vitoria Miñana, Isidro
  • Valero Merino, Caridad
  • Ribas Garcia, Raquel
  • Simó Jordá, Margarita
  • Clavel, Juana
  • Leiva Santana, Carlos
  • Capablo, Jose Luis
  • Gazulla, Jose
  • Padilla, Pablo
  • Loureiro, Carmen
  • Navarro Fernández-Balbuena, Carmen
  • Arias, Manuel|||0000-0002-4938-5402
  • Rabuñal, María José
  • Sobrido, María Jesús
  • Cia, María Teresa
  • Yoldi-Petri, María Eugenia
  • Erro, María Elena|||0000-0002-9707-4190
  • Fontes, Ariadna
  • Rouco Axpe, Idoia
  • Ezkurida Sasieta, Francisco Javier
  • Gómez Esteban, Juan Carlos|||0000-0002-4697-3890
  • Suárez Muñoz, Jose A.
  • Rodríguez Espinosa, Norberto
  • Hernández, Miguel A.
  • Tejera MartÍn, Ingrid
  • Fuentes Garrido, Alberto
  • Aporta, Rafael
  • Domingo, Rosario
  • Casado Naranjo, Ignacio
  • Ruíz Gómez, María Ángeles
  • Amer Ferrer, Guillermo
Niemann-Pick disease type C (NP-C) is a rare, autosomal recessive neurodegenerative disease caused by mutations in either the NPC1 or NPC2 genes. The diagnosis of NP-C remains challenging due to the non-specific, heterogeneous nature of signs/symptoms. This study assessed the utility of plasma chitotriosidase (ChT) and Chemokine (C-C motif) ligand 18 (CCL18)/pulmonary and activation-regulated chemokine (PARC) in conjunction with the NP-C suspicion index (NP-C SI) for guiding confirmatory laboratory testing in patients with suspected NP-C. In a prospective observational cohort study, incorporating a retrospective determination of NP-C SI scores, two different diagnostic approaches were applied in two separate groups of unrelated patients from 51 Spanish medical centers (n = 118 in both groups). From Jan 2010 to Apr 2012 (Period 1), patients with ≥2 clinical signs/symptoms of NP-C were considered 'suspected NP-C' cases, and NPC1/NPC2 sequencing, plasma chitotriosidase (ChT), CCL18/PARC and sphingomyelinase levels were assessed. Based on findings in Period 1, plasma ChT and CCL18/PARC, and NP-C SI prediction scores were determined in a second group of patients between May 2012 and Apr 2014 (Period 2), and NPC1 and NPC2 were sequenced only in those with elevated ChT and/or elevated CCL18/PARC and/or NP-C SI ≥70. Filipin staining and 7-ketocholesterol (7-KC) measurements were performed in all patients with NP-C gene mutations, where possible. In total across Periods 1 and 2, 10/236 (4%) patients had a confirmed diagnosis o NP-C based on gene sequencing (5/118 [4.2%] in each Period): all of these patients had two causal NPC1 mutations. Single mutant NPC1 alleles were detected in 8/236 (3%) patients, overall. Positive filipin staining results comprised three classical and five variant biochemical phenotypes. No NPC2 mutations were detected. All patients with NPC1 mutations had high ChT activity, high CCL18/PARC concentrations and/or NP-C SI scores ≥70. Plasma 7-KC was higher than control cut-off values in all patients with two NPC1 mutations, and in the majority of patients with single mutations. Family studies identified three further NP-C patients. This approach may be very useful for laboratories that do not have mass spectrometry facilities and therefore, they cannot use other NP-C biomarkers for diagnosis.